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1 INTRODUCTION 
 
For a drug to have a pharmacological response, it has to first absorb to the systemic 
circulation, partition into tissues and bind to its target. For some targets, such as 
receptors on the plasma membrane, binding takes place from the extracellular fluids. 
However, there are plenty of intracellular drug targets and for drug to reach them it has 
to also permeate through the plasma membrane and partition into the subcellular 
location in question. Approximately half of all known drug targets are intracellular.  
Examples of intracellular targets of drugs include nucleus for many anticancer drugs 
and gene or antisense therapy, lysosomes for drugs in lysosomal storage disease, 
mitochondria for antiapoptotic or some anticancer drugs or gene therapy, and plasma 
membrane for HIV fusion inhibitors (Breunig et al. 2008, Torchilin 2006). Number of 
compounds reported to have an intracellular target and the localization of the target are 
listed in Table 1. For these drugs, reaching the systemic circulation is not adequate, but 
they have to also permeate through the plasma membrane and preferably sequester into 
a certain subcellular location to induce the pharmacological action. Intracellular 
distribution of these drugs is useful to know in order to evaluate the concentration at the 
site of action. The concentration of the drug in that specific intracellular compartment 
determines the therapeutic effect of a drug while accumulation into another, non-target, 
compartment can result in side effects and lack of response.  
Table 1. Number of compounds reported to have an intracellular target and the 
localization of these targets (Zheng et al. 2011) . 
Localization 
No. of 
compounds 
 % 
No. of 
references 
total  967 100 448 
endolysosomes  226 23 96 
mitochondria 259 27 136 
nucleus 123 13 67 
plasma membrane  162 17 75 
endoplasmic reticulum 
and Golgi apparatus 
37 4 26 
cytosol  59 6 36 
multiple sites  101 10 71 
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The knowledge of intracellular drug distribution and factors affecting it can also be 
utilized in drug development: drugs can be designed to target certain intracellular 
compartments or avoid them. Intracellular targeting strategies are just in its infancy and 
currently the drugs with intracellular targets are usually designed to be plasma 
membrane permeable i.e. they pervade the entire cell and not just the specific 
subcellular compartment (Rajendran et al. 2010). 
Some drugs are substrates to transporters whose binding sites are inside the cell 
(Duvvuri, Krise 2005). In this case, the knowledge of drug distribution can be utilized 
when predicting the role of active transport in the overall transport process. If the 
binding site of a transporter is inside a certain cellular compartment, the rate of transport 
depends on the concentration of the drug in that cellular compartment. One example is 
an efflux transporter P-glycoprotein (MDR1, ABCB1) whose binding site locates in the 
plasma membrane of cells (Raub 2006). 
Drug sequestration into organelles not containing the target of the drug is also suggested 
to be one mechanism causing multidrug resistance in some cancer cells (Duvvuri, Krise 
2005). Lysosomal accumulation of weakly basic anticancer drugs seems to play a major 
role in multidrug resistance of cells, which do not express common efflux transporters, 
such as MDR1, on their plasma membrane (Duvvuri et al. 2005).  Accumulation of 
drugs into non-target compartments results in decreased concentrations in the nucleus, 
which is the site of action for many anticancer drugs. Understanding the mechanisms 
behind drug sequestration in multidrug cancer cells is valuable when designing 
strategies to overcome the multidrug resistance. 
Intracellular distribution of small molecule drugs is not commonly studied (Duvvuri, 
Krise 2005). Perhaps the most frequently used methods are those based on fluorescent 
microscopy so the knowledge of intracellular distribution is somewhat restricted to 
fluorescent compounds (Duvvuri et al. 2004a). Subcellular fractionation is also used, 
but the problem with that method seems to be the diffusion of drug between 
compartments during the fractionation. Despite the lack of research in the field of 
intracellular distribution, the mechanisms that affect the distribution and sequestration 
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of drugs inside cells are quite well understood. Determination of intracellular drug 
concentrations is not routinely demanded when new drugs are being developed, but e.g. 
with certain anti-infective agents, FDA recommends determining the degree of 
intracellular penetration (Food and Drug Administration 1998). 
In this literature review the mechanisms causing intracellular drug sequestration are 
described along with the consequences of intracellular drug sequestration and methods 
that are used to study it. At first some background information about cell biology and 
intracellular trafficking of molecules are introduced. In the end of this review the 
alterations of intracellular distribution of the anticancer drugs in multidrug resistant 
cancer cells are described as an example of the many factors affecting the distribution 
pattern of drugs inside the cells.   
 
 
2 CELL 
 
The cell consists of distinct membrane-enclosed compartments, i.e. organelles, and 
cytosol (Alberts 2002a). The cytosol occupies over half of the total cell volume in 
eukaryotic cells (e.g. 54 % in hepatocytes) and the rest is occupied by organelles. Each 
organelle has its own properties, function and protein composition which can all affect 
the sequestration of drugs into these organelles. Lipid bilayers isolate organelles from 
their environment, and enable specific characteristics of the organelle to be maintained.  
The pH values of the organelles vary from the basic mitochondria to the acidic 
lysosomes (Figure 1). Cytosolic and endoplasmic reticulum pH is near neutral and about 
7.2 (Alberts 2002b). The acidic compartments of the cell include lysosomes, recycling 
endosomes, Golgi network and secretory vesicles (Larsen et al. 2000, Demaurex 2002). 
The most basic compartment is mitochondria, whose pH is about 8 (Llopis et al. 1998). 
An optimal pH is maintained by the balance between active and passive proton transport 
(Demaurex 2002). Diseases or pharmacological compounds can disrupt this balance 
thus resulting in changes in organelles function.  
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Figure 1. Cell organelles and their pH. Modified from Demaurex (2002).  
 
2.1 Membrane trafficking and subcellular organization in cells 
 
Cells are constantly recycling their constituents and newly synthetized material is 
imported to the right destination according to sorting signals included in its structure 
(Rajendran et al. 2010). The same sorting machinery is involved in trafficking of 
proteins from plasma membrane to subcellular compartments through endocytosis. 
Early endosomes act as a sorting station for endocytosed material and depending on the 
membrane interaction and components, which are involved in endosome formation, 
endocytosed material is imported to specific subcellular location. Pathogens, such as 
viruses or toxins, use these same mechanisms to enter subcellular locations and drugs 
can be targeted to certain subcellular compartment by linking a specific sorting moiety 
into its structure.  
 
2.2 Permeation of drugs through the lipid bilayers 
 
A drug has to be able to permeate through the lipid bilayer plasma membrane to get into 
the cell (Duvvuri, Krise 2005). When inside the cell, it has to also permeate through 
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organelle membrane if the target of the drug is inside the organelle. Lipid bilayers 
consist mainly of phospholipids and cholesterol (Krämer et al. 2009). Hydrophobic 
carbon chains of the phospholipids are organized towards inside of the bilayer and 
hydrophilic head groups form the outside of the bilayer.  The hydrophobic core is the 
main barrier for the permeation of hydrophilic compounds.  
Three main pathways of permeation are simple diffusion, carrier-mediated diffusion and 
active transport (Thomae 2007). Simple and carrier-mediated diffusion are passive 
processes which do not require energy and take place along concentration gradient. 
Active transport requires energy and the drug can be transported also against 
concentration gradient. Drugs can also be taken into the cell by endocytosis.  
 
2.2.1 Simple diffusion 
 
Krämer et al, 2009 reviewed two models for simple diffusion of drugs through the lipid 
bilayer: diffusion model and flip-flop model (Figure 2). In the diffusion model, the 
bilayer is assumed to be homogenous lipophilic solvent in which the drug diffuses 
according to Fick’s first law: 
   
           
 
             
, where D is the diffusion coefficient, P is the partition coefficient between bilayer and 
aqueous compartment, h is the thickness of the bilayer and Cd and Cr are concentrations 
in donor and receiver compartments, respectively.  
However, in some cases permeation cannot be explained with this simple model and a 
better fit is achieved with the flip-flop model. Amphiphilic drugs are observed to 
arrange themselves like phospholipids in bilayers, hydrophobic region facing inside and 
hydrophilic outside (Siarheyeva et al. 2006). It is also observed, that polar head groups 
of the phospholipids can have electrostatic interactions with charged drug molecules 
and thus partitioning of the charged form of the drug can be higher than partitioning of 
the neutral form (Lombardi et al. 2009). In the flip-flop model a drug can translocate 
itself between two lipid leaflets, “flip” from the outer leaflet to the inner leaflet or 
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opposite, its hydrophobic moiety facing inside of the bilayer and hydrophilic outside. 
Depending on the kinetics of the translocation and partitioning into the membrane, 
diffusion can be described with either of the models. If the rate of translocation is much 
higher than the rate of partitioning, diffusion is better described with the flip-flop model 
and opposite holds true for the diffusion model.  
 
Figure 2. Flip flop model (on the left) and diffusion model (on the right) for permeation 
of drugs through the lipid bilayer. In the flip flop model, the hydrophilic moiety of the 
amphiphilic drug (light grey) is oriented towards the hydrophilic head groups of 
phospholipids and the hydrophobic moiety (dark grey) towards the hydrophobic carbon 
chains. Drug can translocate itself from the one lipid leaflet to the other and partition 
between lipid leaflets and aqueous phase. In the diffusion model, the molecule partitions 
into lipid bilayer, which is assumed to be homogenous lipophilic solvent.  
 
According to the diffusion model, uncharged drugs are assumed to cross the bilayer 
more easily than charged ones, since they have higher partitioning in lipophilic core of 
the bilayer (Krämer et al. 2009). In the flip-flop model, the probability of flip-flop event 
determines the permeation rate and high dissolution of charged lipophilic drugs into 
polar head groups of the phospholipids is possible, thus enabling also charged species to 
permeate. Size of the drug affects as well, smaller molecules have better permeability 
than larger ones. For example molecules larger than 1 kDa do not permeate through the 
plasma membrane (Bareford, Swaan 2007).  
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Passive diffusion depends also on the organelle in question, since the characteristics of 
the organelle membranes are different. For example nucleus contains pores, which 
allows compounds smaller than 40 kDa to permeate (Keminer, Peters 1999). 
 
2.2.2 Carrier-mediated and active transport 
 
Drugs can also cross the lipid bilayer by transporter proteins or carriers. Transport can 
be either passive or active and it is saturable unlike transport by simple diffusion. Often 
transport is partly diffusional and partly mediated by carrier or active transporter. 
Energy for active transport can be derived from ATP (primary active) or from ion 
gradients (secondary active) (Hediger et al. 2004). Two widely studied transporter 
families are SLC (solute carrier) and ABC (ATP-binding cassette) families. Almost all 
passive transporters, secondary-active transporters and exchangers belong to the SLC 
family, and primary active transporters belong to the ABC family (Huang, Sadée 2006).  
The members of the SLC family carry many natural cellular substances such as amino 
acids, sugars, peptides and organic anions and cations into the cell or out of the 
organelles (Dobson, Kell 2008). Some of them are known to be involved also in the 
drug transportation. For example some antibiotics and cardiac glycosides use carriers 
from the SLC family to entry the cell. Members of the SLC family are also found in the 
mitochondrial membrane and in the membranes of intracellular vesicles (Figure 3) 
(Hediger et al. 2004). 
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Figure 3. Solute carrier (SLC)- and other transporter proteins involved in the permeation 
of drugs or endogenous substances  through the lipid bilayers of the cell (Hediger et al. 
2004). Non-SLC transporters can also locate in the membranes of intracellular 
compartments.  
 
Members of the ABC family transport ions, carbohydrates and drugs out of the cell or 
into cellular organelles. Subcellular locations of ABC transporters are plasma 
membrane, lysosomes, mitochondria, endoplasmic reticulum and peroxisomes (Borst, 
Elferink 2002). The effect of the intracellular ABC transporters on the drug 
sequestration especially in multidrug resistant cancer cells has been widely studied and 
is discussed later in this review.  
 
2.2.3 Endocytosis 
 
If the drug is large or very polar, it can be taken into cell by endocytosis. Endosomes 
formed by the plasma membrane and ingested contents will mature into acidic vesicles 
which can fuse with lysosomes where the molecule is decomposed (Bareford, Swaan 
2007). Fusion with lysosomes can also be avoided depending on the membrane 
interaction and components which are involved in the vesicle formation. This will result 
in accumulation of endocytosed molecule into endosomes from where it can be 
transported to subcellular (non-lysosomal) compartments. Knowledge of the endocytic 
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mechanism can be exploited when developing drugs that are targeted to endosomes or 
lysosomes or designed to avoid them.  
Endocytosis can be clathrin independent or dependent (Figure 4) (Tarragó-Trani, Storrie 
2007). Clathrin-dependent endocytosis (Figure 4B) is more widely studied and better 
understood. Clathrin is a cytosolic protein which coats the vesicles formed when 
material is endocytosed.  The content of clathrin-coated vesicles is then transported to 
early endosomes and after that to late endosomes and lysosomes or Golgi apparatus.  
Clathrin-independent endocytosis can be caveolar or non-caveolar (Tarragó-Trani, 
Storrie 2007). In non-caveolar endocytosis, the lipid raft (plasma membrane 
microdomain) surrounds the endocytosed material which is transported to the early 
endosome for sorting. Caveolae are uncoated cell surface invaginations, a subtype of 
lipid rafts (Figure 4C). Caveosome can transport its contents directly to the endoplasmic 
reticulum or Golgi network, bypassing the early endosome. Alternatively, it can 
transport it contents to early endosomes. Other examples of clathrin-independent 
endocytic pathways are macropinocytosis (Figure 4A) and phagocytosis. 
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Figure 4. Intracellular trafficking after endocytosis by different mechanisms. A) 
Macropinocytosed material form macropinosome which can be fused with lysosome or 
recycle its content to the cell surface. B) In clathrin-mediated endocytosis material is 
first transported to early endosome where it can be delivered to lysosomal pathway or to 
Golgi apparatus. C) In caveloae-mediated endocytosis caveosomes  are formed from 
which endocytosed material can be delivered to endoplasmic reticulum or Golgi 
apparatus or to early endosomes. Modified from Hillaireau, Couvreur (2009). 
 
2.3 Cytoplasm as a diffusion barrier for macromolecules 
 
Cytoplasm is an aqueous compartment, crowded with solutes, soluble macromolecules, 
skeletal proteins and membranes (Verkman 2002). It represents a major barrier for 
diffusion, especially for large compounds such as DNA. For small molecules, e.g. 
fluorescent probe BCECF with molecular weight less than 1 kDa, diffusion in 
cytoplasm was approximately 4 times slower than in water. The main reason for slower 
diffusion turned out to be the probe collisions with intracellular components (molecular 
crowding). For larger compounds, e.g. FITC-dextran with molecular weight of 2000 
kDA, diffusion in cytoplasm was approximately 50 times slower than in water. In 
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addition to molecular crowding, also e.g. binding to intracellular components decreases 
the diffusion rate of DNA and proteins in cytoplasm.   
 
 
3 INTRACELLULAR SEQUESTRATION MECHANISMS OF DRUGS 
 
After permeation through the membrane, a drug can accumulate into specific 
intracellular compartments due to pH partitioning, electrochemical gradient, 
macromolecular binding or active transport (Duvvuri, Krise 2005). The drug can also 
partition into the lipid bilayer. If the drug is taken into the cell by endocytosis, it can 
accumulate in endosomes or lysosomes and possibly be transferred into other organelles 
of the recycling pathway. The mechanisms of intracellular drug sequestration are 
presented in Figure 5. Mechanisms, along with some examples of drugs which are 
utilizing these mechanisms and organelles most likely involved are presented in Table 2. 
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Figure 5. Intracellular sequestration mechanisms of drugs. A) In pH partitioning, a drug 
(grey oval) ionizes due to different pH of the organelle and cytosol and gets trapped 
inside the organelle. B) In electrochemical accumulation, positively charged drug 
accumulates into the organelle due to electrochemical gradient caused by negative 
charge inside organelle. C) In macromolecular binding, a drug binds to e.g. proteins and 
the complex is impermeable and gets trapped into the organelle. D) In active transport, a 
drug binds to the transporter and can be transported into or out from the cell or 
organelle. E) Lipophilic drugs can partition into lipid bilayer. F) In endosomal 
sequestration, after endocytosis, early endosome can fuse with lysosomes or develop 
into recycling endosome. Some toxins can avoid lysosomal pathway after endocytosis 
and get transported to the Golgi apparatus or endoplasmic reticulum instead. Figures A-
C represent organelles and figures E-F whole cells. Figure D can represent both, the 
whole cell or the organelle.  
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Table 2. Intracellular sequestration mechanisms of drugs 
Mechanism Drugs using this 
mechanism 
Organelles which 
are most likely 
involved 
References 
pH partitioning Weakly basic drugs 
with pKa near 
neutrality, e.g. 
daunorubicin 
Acidic vesicles 
such as lysosomes, 
recycling 
endosomes and 
multivesicular 
bodies 
(Gong et al. 2003, 
Altan et al. 1998, 
Chen et al. 2006)  
 
Electrochemical 
accumulation 
Lipophilic cationic 
compounds, e.g. 
TPP linked 
antioxidants 
Mitochondria (Brown et al. 2007, 
Kelso et al. 2001) 
Macromolecular 
binding 
Drugs with affinity 
to the nuclear or 
mitochondrial 
DNA, e.g. 
doxorubicin  
 
Drugs with affinity 
to cytoskeleton e.g. 
paclitaxel  
Nuclei, 
mitochondria, 
cytosol 
(De Beer et al. 
2001, Lansiaux et 
al. 2002, Ashley, 
Poulton 2009, 
Jordan, Wilson 
2004)  
 
Transport processes Substrates of 
transporters e.g. 
daunorubicin as a 
MDR1 substrate or 
doxorubicin as a 
MRP1 substrate 
Cytoplasmic 
vesicles, such as 
lysosomes and 
multivesicular 
bodies 
 
(Shapiro et al. 
1998, Meschini et 
al. 2000, Gong et 
al. 2003, Van Luyn 
et al. 1998, Chapuy 
et al. 2008)  
Partitioning into 
lipid bilayers 
Highly lipophilic 
drugs 
Plasma membrane, 
organelle 
membranes  
(Wils et al. 1994) 
Endosomal 
sequestration 
Toxins, e.g. Shiga 
toxin 
 
Folic acid, 
cholesterol 
 
Drug carrier 
systems taken into 
cell by endocytosis, 
e.g. nanoparticles  
Endosomes, 
lysosomes, Golgi 
apparatus, 
endoplasmic 
reticulum 
(Tarragó-Trani, 
Storrie 2007, 
Bareford, Swaan 
2007, Hillaireau, 
Couvreur 2009)  
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3.1 pH partitioning  
 
pH partitioning, or ion trapping, is based on the different permeability of unionized and 
ionized form of the molecule through the lipid bilayer restricting two compartments 
with different pH (Duvvuri, Krise 2005). The ionization degree of weakly acidic drug in 
certain pH can be calculated with Henderson-Hasselbalch equation: 
           
[  ]
[  ]
   
, where pKa is the logarithmic acid dissociation constant of the drug, and [A
-
] and [HA] 
are concentrations of ionized and molecular form of the drug, respectively. As can be 
seen from the Henderson-Hasselbalch equation, the pKa of the drug and pH difference 
of the compartments dictate the ionization degree. For pH partitioning to occur, drug 
must have pKa close to pH values of the compartments and permeability of ionized and 
unionized form must be clearly different. 
pH partitioning is most likely to happen with weakly basic compounds between 
lysosomes and cytosol, because of the large pH difference between them (Duvvuri, 
Krise 2005). Since pH in the lysosomes can be as low as 4.5-5 (Mellman et al. 1986), 
weakly basic compounds can ionize and accumulate there. Also other acidic vesicles, 
such as endosomes, can sequester drugs. For weakly acidic compounds, accumulation 
can occur into mitochondria, but the degree of accumulation is not expected to be as 
large since the pH difference of mitochondria and cytosol is smaller, only about 0.8 
whereas the difference between lysosomes and cytosol can be 2 or larger.  
Lysosomal sequestration is a quite common phenomena, since many drugs marketed 
today are weakly basic amines, containing at least one basic nitrogen (Kaufmann, Krise 
2006). In malaria and Q-fever, the target of the drug is inside lysosomes and this 
accumulation is favorable. However, more common is the reduced interaction with the 
target causing e.g. multidrug resistance in some cancer cells. For example, daunorubicin 
nuclear concentration in multidrug resistant human U-937 myeloid leukemia cells was 
2.5-fold to threefold smaller than in drug sensitive counterparts, due to daunorubicin 
pH-partitioning into lysosomes (Hurwitz et al. 1997). 
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Amine-containing drugs can accumulate into lysosomes by passive diffusion or active 
transport from the cytosol (Kaufmann, Krise 2006). They can also undergo 
autophagocytosis, where autophagic vacuoles (cytolysosomes) are formed and fused 
with lysosomes or endocytosis from extracellular fluid. The accumulation degree by 
active transport, endocytosis or autophagocytosis is usually not that large, since there 
are passive mechanisms which balance them. One example of a compound 
accumulating into lysosomes is weakly basic lysotracker red, which concentration in 
lysosomes was about 20-fold larger than in extracellular medium (Duvvuri et al. 2004a). 
In addition to pH-partitioning, there could also be some other mechanisms responsible 
for accumulation into lysosomes, since experimentally observed concentrations are 3-15 
times higher than the pH-partitioning theory predicts (Duvvuri, Jeffrey 2005).  
At least two important parameters affecting drug sequestration into lysosomes can be 
named: pKa and permeability parameter called α (Kaufmann, Krise 2006). The higher 
the pKa of a compound, the greater is its accumulation into lysosomes if permeability 
through lipid bilayer is similar. Duvvuri et al. (2005) studied the accumulation of 
weakly basic model compounds (aminoquinoline isomers) to lysosomes in human 
leukemic cell line (HL-60) and observed lysosome/cytosol concentration ratios of about 
4, 20, 50 and 60 when pKa values of a compound were 5, 6, 7.4 and 9, respectively. The 
parameter α can be calculated by dividing the intrinsic octanol-water partition 
coefficient of a fully ionized base by that of unionized base. If α is 1, the partition 
coefficient of ionized and unionized form is the same, and thus the permeability can be 
assumed to be equal. The higher the value of α, the lower is the accumulation into 
lysosomes. Duvvuri et al. (2004b) studied the effect of α to lysosome/cytosol amount 
ratio of compounds in HL-60 cells and observed ratios of approximately 40, 5, 0.7 and 
0.1 when α-values were 0.004, 0.02, 1 and 1.4, respectively.  These effects of pKa and α 
are reasonable, since when pKa of a basic drug is increased, its ionized fraction in acidic 
lysosomes is increased, and if the ionized fraction cannot cross lipid bilayers, it 
accumulates into lysosomes. However, when permeability of the ionized and unionized 
form of the drug is similar (α is near 1), the ionized form cannot accumulate into 
lysosomes.  
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Another example of acidic vesicles presumably able to sequester drugs by pH-
partitioning is multivesicular bodies (MVB) (Chen et al. 2006). Chen et al. used human 
erythroleukemic cells (K562) to study doxorubicin vesicular transport. K562 cells have 
MVB which are involved in endocytic trafficking and release their contents to 
extracellular medium after fusion with plasma membrane. MVBs are acidic vesicles to 
which drugs can accumulate due to pH-partitioning or membrane binding and 
doxorubicin efflux from the cell is at least partly mediated by MVBs. 
 
3.2 Electrochemical accumulation 
 
Accumulation due to electrochemical gradient can occur into mitochondria, since there 
is a net negative membrane potential in the inner membrane of mitochondria (Alberts 
2002a). Cationic molecules can therefore accumulate into mitochondria, if they are 
lipophilic enough to cross the membrane.  
The membrane potential of mitochondria is about 130-150 mV in living cells with inner 
side being negative (Murphy, Smith 2000). Mitochondrial sequestration can be 
calculated with Nernst equation: 
                        
  
  
    
[      ]  
[      ]   
  
, where R is the universal gas constant, T is the temperature, z is the number of 
electrons transferred in the reaction, F is the Faraday constant and [cation]in and 
[cation]out are concentrations of cations inside and outside of the mitochondria, 
respectively. In physiological temperature 37 °C, constant 
  
  
        and 
concentration inside mitochondria can be 100-fold or higher.  
Mitochondrial accumulation of lipophilic cations can be utilized when developing drugs 
targeted to mitochondria. One widely used cation known to accumulate into 
mitochondria is triphenylphosphonium cation (TPP) (Murphy 2008). Brown et al. (2007) 
targeted antioxidant lipoic acid (LA) to mitochondria by conjugating it to TPP. Study 
was done with isolated rat liver mitochondria and accumulation into mitochondria was 
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several hundred-fold, consistent with the Nernst equation. Also Kelso et al. (2001) used 
TPP to target antioxidant ubiquinone to mitochondria of human osteosarcoma 143B 
cells. Uptake of ubiquinone-TPP complex (mitoQ) was decreased about 50 % by 
disrupting mitochondrial membrane potential with carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) indicating the importance of the membrane 
potential in mitochondrial accumulation.  
Measuring mitochondrial accumulation in whole cells is challenging, since fractionation 
of cell depolarizes mitochondria and drug can be rapidly released (Murphy 2008). This 
release can be minimized using 4-iodobutyltriphenylphosphonium (IBTP), a TPP linked 
iodoalkyl system, which forms a stable thioether linkage with proteins. With IBTP it has 
been shown that almost all IBTP within cells is located in the mitochondria. Another 
challenge in whole cell experiments is that accumulation of lipophilic cations can 
disrupt mitochondrial function which sets the limits to the concentrations that can be 
used in experiments. Naturally, also when considering the drug therapy, the drug has to 
be potent enough to have the pharmacological effect with a concentration that is small 
enough not to disrupt mitochondrial function. 
 
3.3 Macromolecular binding 
 
Macromolecular binding can affect accumulation if the drug-macromolecule complex is 
membrane impermeable or if the permeability of the complex is reduced compared to 
the free drug (Duvvuri, Krise 2005). The binding of drugs to macromolecules can 
improve therapeutic effect if macromolecule is the target, however this is not always the 
case and therapeutic response can also decrease due to undesirable binding to non-target 
macromolecules. Only unbound drug can bind to its target and achieve the required 
response. 
One example of macromolecular binding is the accumulation of DNA-binding drugs, 
such as doxorubicin, to nuclei (De Beer et al. 2001, Lansiaux et al. 2002). For example, 
95 % of the total doxorubicin was bound to DNA in tumor tissue (Laginha et al. 2005). 
Reversible drug-DNA-interactions can be divided into three major classes: electrostatic 
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interactions, intercalation or groove-binding (Reddy et al. 1999). Drugs can also 
irreversibly bind to DNA. Knowledge of the interaction mechanisms has improved the 
possibilities to target e.g. anticancer drugs to the nucleus. Introduction of a positive 
charge to improve electrostatic interaction or linkage of DNA targeting ligands, such as 
intercalators or DNA-groove binders, into drugs are examples of strategies used to 
target DNA (Zutphen, Reedijk 2005). 
Recently, it was shown that anticancer drugs, such as doxorubicin, bind also to 
mitochondrial DNA in addition to nuclear DNA (Ashley, Poulton 2009). The authors 
observed that doxorubicin concentration-dependently quenched fluorescence of DNA-
binding dye PicoGreen in mitochondria of HCA2 human fibroblasts, possibly by 
displacing PicoGreen from the mitochondrial DNA. Fluorescence decreased 
approximately 50 % when doxorubicin concentration was 0.7 µM and 75 % when 
concentration was 3.5 µM compared to 100 % fluorescence when PicoGreen was 
incubated without doxorubicin.  
Drugs can also bind to proteins in other organelles, to cytoskeleton in cytosol or to 
phospholipids in the plasma membrane, endoplasmic reticulum or Golgi apparatus 
(Zheng et al. 2011). Again, an example is found among the anticancer agents. Vinca 
alkaloids and paclitaxel are bound to microtubule in cytoskeleton disrupting the mitosis 
of cancer cells (Jordan, Wilson 2004).  
Melanin pigment is a polymer found in hair, skin and eyes of the animals and it has 
been demonstrated to bind to many drugs both in vitro and in vivo (Karlsson, Lindquist 
2013). Melanin is also found in the pigmented part of the brains. Many basic drugs such 
as chloroquine, amphetamine and atropine bind to melanin and may be accumulated 
into tissues containing melanin. Organic amines and metallic ions show usually the 
highest affinity to melanin. Accumulation of drugs into tissues containing melanin has 
been observed to lead to ocular toxicity and skin pigmentation and its possible role in 
neurodegeneration has also been studied. Intracellular organelles responsible for the 
synthesis of melanin are melanosomes and drug sequestration to these organelles 
because of melanin binding can be one factor decreasing the cytotoxic effect of 
anticancer drugs doxorubicin and daunorubicin on melanocytes (Svensson et al. 2003). 
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3.4 Transport processes 
 
Accumulation due to active transport can occur for substrates of transport proteins. 
Transport proteins are located in the plasma membrane and in the membranes of 
intracellular compartments and use energy from e.g. ATP hydrolysis or ion gradient to 
transport substrates against concentration gradient (Alberts 2002b). Efflux transporters, 
such as MDR1 or multidrug resistant protein 1 (MRP1), carry substrates out of the cell 
and uptake transporters, such as organic anion transporter, carry substrates into the cell. 
These transporters are widely studied for their ability to either enhance drug uptake into 
cells or inhibit it when localized in the plasma membrane of the cells.  
Studies have shown the existence of transporter proteins also in intracellular 
compartments, but it is unclear whether these proteins are functional there or if they are 
just on their way to the plasma membrane after biosynthesis (Duvvuri, Krise 2005). 
Ferrao et al. (2001) found out that MDR1 inhibitors could alter daunorubicin 
intracellular distribution in acute myeloid leukemia cells, and that total MDR1 
(intracellular and surface) correlated better with the efflux than only surface MDR1. 
Based on these results, the authors suggested that the intracellular MDR1 is functional. 
Shapiro et al. (1998) made the same conclusion by demonstrating that daunorubicin 
accumulated in cytoplasmic, non-endocytic vesicles of multidrug resistant Chinese 
hamster ovary CHrC5 cells can be released with MDR1 inhibitor. Active transporters 
are suggested to play a role in drug distribution in nucleus, lysosomes, endosomes and 
mitochondria (Zheng et al. 2011). 
 
3.5 Partitioning into lipid bilayers 
 
If a drug has very high lipophilicity it can partition into lipid bilayers i.e. membranes 
that restrict organelles (Zheng et al. 2011). Sawada et al. (1999) studied the permeation 
of pyrrolopyrimidine antioxidants with different lipophilicity through Madin-Darby 
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canine kidney (MDCK) cell monolayers. Different lipophilicities were obtained by 
placing hydrophobic or hydrophilic groups, or groups capable of hydrogen bonding, to 
the structure.  Compounds with more hydrophobic structure had decreased permeability 
compared to compounds with more hydrophilic groups and more hydrogen bonding 
groups, when considering both disappearance of the compound from donor side and its 
appearance on the receiver side. For example, when calculated log P values were 
increased from 4 to 6 to 8, the apparent permeability coefficients were decreased from 
11 to 5 to 1 x10
-6 
cm/s, respectively. The authors suggested this to be the consequence 
of increased cell partitioning of lipophilic compounds.  
Wils et al. 1994 (Wils et al. 1994) reported similar results. They studied the permeation 
of drugs and chemicals with different lipophilicity through cell monolayers and found a 
cut-off value for log D of a compound to be 3.5 and for drugs with log D higher than 3.5 
(lipophilicity increases as log D increases) permeability decreased with increasing 
lipophilicity. 
However, studies with very lipophilic drugs are not that easy to execute, and drug 
adsorption into plastic devices and low solubility of the highly lipophilic compounds 
can complicate the interpretation of results, especially in permeation studies.  
 
3.6 Membrane trafficking and endosomal sequestration 
 
Retrograde trafficking pathway from endosomes to Golgi and ER has been largely 
studied with toxins and research of the utilization of these mechanisms in drug transport 
is also underway (Tarragó-Trani, Storrie 2007). If the drug is taken into cell by 
endocytosis it can be delivered progressively to early endosomes, late endosomes and 
lysosomes, where it is degraded but this path can also be avoided or minimized (Figure 
4). Some toxins, such as Shiga toxin, are taken into the cell in clathrin-coated pits and 
can be transported into Golgi apparatus bypassing the lysosomal path and degradation. 
Degradation in lysosomes is also avoided by some toxins using caveolar uptake to gain 
entry to the smooth endoplasmic reticulum or Golgi apparatus. In theory, proteins from 
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these toxins could be used as a carrier for drugs targeting the Golgi apparatus and 
endoplasmic reticulum. 
Nanoparticles can also be taken into the cell by endocytosis (Hillaireau, Couvreur 2009). 
Depending on the physicochemical properties of the drug and carrier, the target of the 
drug can be e.g. cytosol or lysosomes. Endocytosis can occur by clathrin-mediated- or 
caveolar pathway or by macropinocytosis (Figure 4). If endocytosis occurs by clathrin-
mediated pathway or macropinocytosis, the target is usually lysosomes or cytosol. 
When using caveolar pathway, the target can be the Golgi apparatus or endoplasmic 
reticulum.  Folic acid, albumin and cholesterol are examples of ligands internalized by 
caveolar endocytosis (Bareford, Swaan 2007). Internalization pathway can be controlled 
by physicochemical properties of the drug-carrier complex, such as the size and surface 
charge of the nanoparticle or by attaching targeting ligands into the surface of the 
nanoparticle (Hillaireau, Couvreur 2009). 
 
 
4 CONSEQUENCES OF DRUG SEQUESTRATION INTO ORGANELLES 
 
Intracellular sequestration of drugs can affect pharmacological action, metabolism and 
excretion if the drug is sequestered away from the site of action. The fraction available 
for these processes decreases which can cause lack of effect or decreased metabolism 
and excretion. Also other pharmacokinetic parameters of a drug can be altered due to 
sequestration into organelles. Accumulation of drugs into non-target organelles and 
their toxicity to these organelles can cause side-effects. Also phospholipidosis, induced 
by accumulation, can cause side-effects or drug-drug interactions as discussed later in 
this chapter. Finally, efficacy of transporters depends on the substrate concentration at 
the binding site, which can be altered due to accumulation into the organelle. 
Sequestration into organelles should be taken into account when discrepancies in 
behavior of drug are observed. 
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4.1 Alterations in pharmacokinetics 
 
Apparent volume of distribution is usually very large if drug accumulates into 
organelles (Funk, Krise 2012). By definition, apparent volume of distribution can be 
calculated with equation:    
 
 
, where A is the amount of the drug in the body and C 
is the concentration of the drug in plasma. Since the accumulation of drug into 
intracellular sites decreases the plasma concentration, volume of distribution increases.  
Partition coefficient Kp, calculated from total intracellular and extracellular 
concentrations, increases because of intracellular sequestration. If the drug is taken into 
the cell by passive diffusion and no transport or metabolism processes are involved, Kp 
is assumed to be 1 i.e. concentration of unbound drug is the same in extracellular and 
intracellular spaces (Chu et al. 2013). However, sequestration caused by e.g. 
partitioning of drug into lipid membranes causes Kp values greater than unity, since the 
total intracellular concentration increases. If this deviation from unity is not taken into 
account, it can complicate e.g. the prediction of drug effects or transporter activity. 
However, it should be noted that under steady-state conditions intracellular 
sequestration does not change the unbound concentration in the cytosol, only total 
intracellular concentration is changed. 
Lag-times observed with some drugs can be a consequence of sequestration. Some 
sequestration processes can be saturable. For example, pH-partitioning into lysosomes 
depends on the pH-gradient between lysosomes and cytosol. This pH-gradient is 
maintained by membrane bound ATPases and if buffering capacity of these ATPases is 
exceeded, it may cause saturable sequestration of lipophilic amines into lysosomes 
(Hallifax, Houston 2007). Saturable sequestration into organelles has been suggested to 
cause delayed response to drug therapy if sequestration site is not the site of action 
(Kaufmann, Krise 2006). This mechanism may cause lag-time observed with e.g. 
antidepressants, since saturation of lysosomal sequestration takes time, and only after 
this saturation, plasma concentration of antidepressants rises to therapeutic level.  
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Sequestration can also increase the half-life of the drug in the body (Kaufmann, Krise 
2006). Sequestered drug is not available for metabolism and can act as a reservoir, from 
where the drug is slowly released.  
 
4.2 Phospholipidosis 
 
The function and structure of the organelle can change if there is extensive 
accumulation of drugs into it (Funk, Krise 2012). One extensively studied alteration is 
phospholipidosis. In drug-induced phospholipidosis, a cationic amphiphilic drug (CAD) 
that accumulates into lysosomes inhibits lipid metabolism there, resulting in 
accumulation of phospholipids into lysosomes and consequently increase in the volume 
of the lysosomes. The increase in lysosomal volume causes the increase in cellular 
uptake of compounds that are sequestered into lysosomes and drug-drug interactions or 
toxicity may follow.  
Phospholipidosis occurs most commonly in lungs and liver, since they have the highest 
abundance of lysosomes, but there is no clinical evidence that CAD-induced 
phopholipidosis is detrimental to organs (Reasor, Kacew 2001). 
  
4.3 Effect to transport processes 
 
Intracellular sequestration is important to consider also when interpreting the results of 
transport experiments across monolayers with efflux transporters (Chu et al. 2013). 
Affinity of a drug to efflux transporter can be described with parameter Km. Km values 
calculated using extracellular concentrations can vary greatly depending on 
experimental conditions and transporter expression. If Km values are calculated using 
intracellular concentrations, i.e. concentration in the site of action, more consistent 
results are obtained.  
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It is assumed that MDR1 substrate binding takes place in plasma membrane of cells 
(Hennessy, Spiers 2007). Consequently, partitioning of drugs into lipid membranes can 
improve the efficiency of MDR1 since the concentration of substrate in the site of 
action is increased. Inversely, if drug partitioning into lipid bilayers is scarce, efflux by 
MDR1 transporter can be assumed to be less efficient. Hence, the knowledge of the 
intracellular distribution of drugs is useful to know in order to predict the role of active 
transport in the overall transport process. 
 
 
5 METHODS FOR STUDYING INTRACELLULAR DRUG DISTRIBUTION 
 
5.1 Microscopic imaging methods 
 
Fluorescence microscopy is commonly applied method when studying intracellular 
distribution of fluorescent compounds in cultured cells (Duvvuri et al. 2004a). It is a 
relatively easy method and it can be done with living cells, enabling one to study the 
kinetics of the drugs. However, there are some limitations. The compounds studied must 
have sufficient fluorescence, quantification is difficult and assay is sensitive to changes 
in pH, ionic strength and noncovalent interactions. Fluorescence can also be lost due to 
metabolism of the compound or self-quenching reactions. Also, when using 
fluorescence labels, labeling can alter the distribution of drug. For example, lysosomal 
sequestration of drugs in whole cells or in isolated lysosomes, have been studied with 
methods based on fluorescence (Kaufmann, Krise 2006). 
Confocal Raman microscopy and secondary ion mass spectroscopy are more sensitive 
and general imaging methods, which are independent of fluorescence (Zheng et al. 
2011). However, their use in intracellular drug distribution studies is still quite scarce.  
 
25 
 
5.2 Subcellular fractionation 
 
Subcellular fractionation can separate the organelles based on their different physical 
properties (Pasquali et al. 1999). It consists of two steps: homogenization of cells and 
fractionation of the cell homogenate by centrifugation steps. Limitations in this 
approach are that it is rather low-throughput method and similar properties of different 
organelles, such as similar density of plasma membranes, Golgi membranes and 
endoplasmic reticulum, can complicate fractionation. Also different cytoskeletal 
organization in tissue cultured cells commonly used in research makes fractionation 
challenging. Efforts are made to overcome these challenges by e.g. density shift 
methods, immunoisolation or flow electrophoresis. Diffusion of the drug out from the 
organelle during isolation procedure can also be a problem with fractionation based 
methods. The advantage of subcellular fractionation methods is that analysis of non-
fluorescent compounds is also possible. Quantification can be done with e.g. HPLC or 
mass spectrometry. 
 
5.2.1 Classical subcellular fractionation 
 
Classical subcellular fractionation involves homogenization of cells and fractionation of 
homogenate using sucrose density gradient (Figure 6) (Pasquali et al. 1999). 
Homogenization is important step and efforts should be made to prepare an ideal 
homogenate with no aggregates which can be lost during initial centrifugation steps for 
removal of nuclei and intact cells. Homogenization should also be mild enough to 
preserve the functionality of proteins and enzymes in the organelle. Postnuclear 
supernatant is centrifuged with sucrose density gradient. Membranes from different 
organelles have different density based on their protein to lipid ratio and composition. 
Gradient medium affects the degree of separation and most commonly used medium is 
sucrose. Separation can be based on velocity centrifugation, where the particle size and 
density affects the time it takes to pellet them, or equilibrium centrifugation, where 
particle moves into certain position in the gradient determined by its density. Validation 
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of fractionation protocol can be done with Western blotting, where antibodies against 
established organelle markers are used.  
 
 
Figure 6. Classical subcellular fractionation using sucrose gradient. Cells are scraped 
and homogenized and after that, nuclei were removed by centrifugation. Postnuclear 
supernatant (PNS) is loaded on top of a sucrose density gradient to separate subcellular 
organelles. Modeled from Pasquali et al. (1999). 
 
One study utilizing density gradient centrifugation is conducted by Duvvuri et al. 
(2004a), who incubated human leukemic U-937 cells with 5 µM lysotracker red or 0.5 
µM doxorubicin for 2 hours and homogenized and fractionated cells into cytosolic, 
nuclear and lysosomal fractions. The concentration of drugs in fractions was measured 
by HPLC with fluorescence detection. They found out that lysotracker red was 
predominantly associated with lysosomes (concentration in lysosomes about 11 µM vs. 
in cytosol and nucleus up to 1 µM) while doxorubicin predominantly associated with 
nucleus (concentration in nucleus about 1.5 µM vs. in cytosol about 0.5 µM and in 
lysosomes about 0.25 µM).  
27 
 
 
5.2.2 Magnetic capture technique 
 
Duvvuri and Jeffrey (2005) developed a method for studying the lysosomal 
sequestration of non-fluorescent compounds known to be accumulated into lysosomes: 
quinacrine and lysotracker red. At first, they incubated 1 µM compounds with multidrug 
resistant human acute promyeloid leukemia (HL-60) cells. Then they isolated lysosomes 
using iron-dextran particles which were taken up in the cell by endocytosis and thus 
concentrating in the lysosomes. Cells were homogenized, nuclei were pelleted and 
magnetic chromatography was used to capture iron-containing lysosomes from post-
nuclear supernatant. Analysis was done with HPLC and the concentrations in lysosomes 
were 766 ± 69 µM for quinacrine and 60 ± 1.8 µM for lysotracker red. 
 
5.2.3 Immunoisolation 
 
Immunoisolation technique uses antibodies to fractionate organelles (Pasquali et al. 
1999). Antibodies against selected antigens in organelles are used to capture the 
organelles. If antigen can be found in several organelles, pre-fractionation can be used 
for initial separation of organelles. There are different solid supports for 
immunoisolation, with magnetic beads being the most commonly used. Antibody is 
bound to the solid support and the complex is used to retrieve organelle of interest. The 
isolation of plasma membranes (Figure 7) (Lawson et al. 2006), mitochondria (Hornig-
Do et al. 2009) and peroxisomes (Wang et al. 2012) are examples of immunoisolation 
with magnetic beads. With immunoisolation, very high purity of fractions can be 
achieved but the high cost and availability of specific antibodies can limit its use. 
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Figure 7.Isolation of plasma membranes using immunoisolation with magnetic beads 
(Lawson et al. 2006). (a) Magnetic beads with immobilized protein. (b) Magnetic beads 
are incubated with antibody against protein. (c) Cells or tissue. (d) Plasma membrane 
vesicles are recovered after homogenization. (e) Magnetic beads with immobilized 
antibody bind to proteins in plasma membrane vesicles and magnet is applied to isolate 
these complexes. (f) Membrane proteins are removed from complex by selectively 
solubilizing them. (g) Solubilized plasma membrane proteins are available for further 
analysis.  
 
5.2.4 Electromigration 
 
Electromigration is based on different charge of membrane vesicles from different 
organelles. This difference in charge results in different electrophoretic mobility 
(Pasquali et al. 1999).  
In free flow electrophoresis (FFE), cell homogenate or fractions can be injected into a 
buffer between anode and cathode and membrane particles migrate in the electric field 
according to their membrane potential (Pasquali et al. 1999). FFE enables large amounts 
of material purified with high speed but it is usually not possible to use it as one-step 
technique for purification. FFE have been used in purification of plasma membrane 
vesicles and endosomes, most commonly used in combination with other methods. 
Quite recently, also purification of peroxisomes (Islinger et al. 2009) and mitochondria 
(Zischka et al. 2006) have been conducted with FFE. 
Extended applications of FFE include density gradient electrophoresis (DGE) and 
immune free flow electrophoresis (IFFE) (Pasquali et al. 1999). In density gradient 
electrophoresis (DGE), homogenate is layered within sucrose gradient and the gradient 
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is separated by anode and cathode, resulting in the migration of membrane vesicles 
based on their density and membrane potential. DGE has been used to purify organelles 
belonging to lysosomal/endosomal pathway (Tulp et al. 1998). Limitations with DGE 
include long separation times and quite poor resolution. In immune free flow 
electrophoresis (IFFE) homogenate is incubated with antibodies against organelle 
markers prior FFE, resulting in reduced electrophoretic mobility of antigen-antibody 
complex. IFFE has been used to isolate rat hepatic peroxisomes (Völkl et al. 1997). As 
with other techniques using antibodies, the cost can limit IFFE’s large scale use in 
purification of organelles. 
 
5.2.5 Fluorescent activated organelle sorting 
 
Fluorescent activated organelle sorting (FAOS) combines the labeling of organelles 
with fluorescent probes and separation of them on the basis of that (Böck et al. 1997). 
Usually the separation is done on the basis of physical properties, e.g. the density of 
intracellular membranes, and so the organelles with similar physical properties are hard 
to distinguish. In FAOS a fluorescent dye which accumulates in the organelle of interest 
is first incubated with cells which are then homogenized and subcellular fractionation is 
done by centrifugation and sucrose gradient step. After that, fractions are sorted in a 
flow cytometer (Figure 8), in which droplets of liquid to be tested are analyzed and if 
they are fluorescent, they are charged positively or negatively. The sorting is done 
electrically and it will further improve the purity of the fraction. In addition to purifying 
endosomes, FAOS has been used to purify secretory granules from mouse anterior 
pituitary cells (Gauthier et al. 2008). Sensitivity can be a problem, since small 
organelles can contain only small amounts of fluorescent probes to be detected by the 
device. 
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Figure 8. Flow cytometer sorts the droplets of test suspension into those containing 
fluorescent dye molecules and those not containing. Modeled from Böck et al. (1997).  
 
5.3 Computational models 
 
Computational models for predicting intracellular drug distribution can be divided into 
statistically based regression models and mechanism-based physiological models 
(Zheng et al. 2011).  
Statistically based regression models, such as quantitative structure-activity relationship 
(QSAR) models, are used to predict quantitatively and qualitatively the existence of a 
drug in certain subcellular organelle (Zheng et al. 2011). Training set is used to provide 
the distribution pattern of drugs based on the physicochemical properties of the drugs. 
This model can then be used with different test set by using their physicochemical 
properties as input parameters.  
Mechanism based physiological models predict distribution according to mass transfer 
calculations using Fick’s law of diffusion or Nernst-Planck equation (Zheng et al. 2011). 
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Reliability and accuracy of a model depends largely on the quality of the input data and 
different experimental approaches can result in large differences in that (Zheng et al. 
2011). Therefore universal models are hard to develop.  
 
 
6 ALTERATIONS IN DRUG DISTRIBUTION IN RESISTANT CANCER CELL 
LINES 
 
Understanding the mechanisms responsible for drug resistance in cancer cells can help 
to develop drugs that are not prone to resistance. Many cancer cells are more sensitive 
to anticancer drugs than normal cells, which enables drug therapy to destroy tumors but 
not normal cells (Simon et al. 1994). However, cancer cells can develop resistance and 
become less sensitive to anticancer drugs.  Multidrug resistance is most likely 
multifactorial (Duvvuri, Krise 2005, Gong et al. 2003). There are many suggested 
characteristics causing multidrug resistance, such as decreased accumulation of drug, 
increased DNA repair and apoptosis defects. Also intracellular distribution differences 
between sensitive and resistant cells are suggested to cause multidrug resistance and the 
reasons for these differences are discussed in this chapter. Examples of hypothesized 
drug sequestering organelles in different multidrug resistant cells are provided in Table 
3. 
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Table 3. Hypothesized drug sequestering organelles in different multidrug resistant cell 
lines (Duvvuri, Krise 2005). 
Cell line  Sequestering organelles 
NIH/3T3  lysosomes, Golgi, ER 
DKLP  cytoplasmic vesicles 
CHO lysosomes  
MCF-7  Golgi, lysosomes, recycling endosomes  
V-79  cytoplasmic vesicles 
HL-60  Golgi, mitochondria, lysosomes  
P388  Golgi, secretory vesicles 
KB3-1 Golgi, lysosomes  
U 937  lysosomes  
EPG85  secretory vesicles 
SW-1573  cytoplasmic vesicles  
AUXB1  cytoplasmic vesicles  
K562  lysosomes, mitochondria, Golgi  
LoVo  Golgi  
CEM  lysosomes, Golgi 
A2780  Golgi 
PKSV-PR  lysosomes  
MES-SA  lysosomes  
Bone Marrow  cytoplasmic organelles  
AML cells  Golgi  
 
6.1 Difference in cytoplasmic pH  
 
Many cancer cells have lower cytoplasmic pH than normal cells (Larsen et al. 2000). 
Altan et al. (1998) measured pH in the cytosol of human MCF-7 breast cancer cells and 
multidrug resistance MCF-7/ADR cells and observed the cytosolic pH in drug sensitive 
MCF-7 cells to be 6.75±0.3 whereas in resistant MCF-7/ADR cells it was 7.15±0.1. The 
acidification of cytosol in cancer cells improves the accumulation of weakly basic 
anticancer drugs to the cell, if ionized form of the drug is less permeable. If this 
acidification is abolished, like it is in resistant cells, accumulation decreases and this in 
turn can affect the saturable processes possibly dictating the intracellular distribution of 
drugs. With MCF-7 cells, accumulation of adriamycin into drug sensitive cells was 
about 2.5-fold greater than into resistant ones. Since intracellular concentrations are 
higher in sensitive cells, capacity of saturable processes such as vesicular transport may 
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be exceeded and concentration in cytoplasm increases. Cytosolic pH affects also the pH 
gradients between cytosol and organelles, which is important factor in intracellular 
distribution of anticancer drugs. 
Changes in cytoplasmic pH can affect also vesicular function. Cosson et al. (1989) 
studied the effect of low cytoplasmic pH on the endocytosis and recycling of transferrin 
in hamster lung fibroblast (CCL39) cell line. Transferrin was used since it is a marker of 
receptor–mediated endocytosis using clathrin-coated pits. Researchers found out that 
the rate of transferrin accumulation in acidified mutated cells lacking Na
+
/H
+
 exchange 
activity was decreased 80 % compared to mutant cells that were not acidified. Also 
recycling of the internalized transferrin from the Golgi apparatus to the cell membrane 
was inhibited in acidified cells. They suggested the reason to be the slower withdrawal 
of clathrin-coated pits from the cell surface or organelle membranes in acid 
environment. Hansen et al. (1993) reported similar results with human Hep-2 carcinoma 
cells and transferrin and deduced that acidification of cytoplasm paralyzes clathrin to 
the membrane-bound state. If cytoplasm of drug sensitive cancer cells is more acidic, 
vesicular transport of drug out from the cell could be decreased compared to resistant 
cells and this can be one contributor to the multidrug resistance.  
 
6.2 Difference in lysosomal pH 
 
Many anticancer drugs are weakly basic with pKs between 7 and 9 (Larsen et al. 2000). 
Consequently, they can accumulate into acidic organelles because of the pH partitioning. 
The unionized fraction of the drug molecules can permeate through the membranes of 
cell and intracellular organelles. After permeation into acidic organelle, the molecule 
ionizes and accumulates there, since the permeability of the ionized form is lower than 
the unionized form. In drug sensitive cancer cell lines, the pH of lysosomes is disrupted 
and near to cytosolic pH whereas in resistant cell lines the pH of lysosomes is re-
established to normal acidic pH (Table 4) (Duvvuri et al. 2005). Weakly basic 
anticancer drugs, such as daunorubicin, accumulate into acidic lysosomes in resistant 
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cells and concentration in target-site (nucleus) is decreased. This mechanism also 
protects the normal non-transformed cells from the cytotoxic effects of anticancer drugs. 
Table 4. Intracellular pH gradients in multidrug resistant and sensitive cancer cells 
(Duvvuri, Krise 2005). 
  
Lysosomes  Cytosol 
 Lysosome to 
cytosol pH 
differential  
Non-transformed cells 
3T3 fibroblasts  <5,0  7,40 > 2,4  
Transformed cells (drug sensitivea and MDRb) 
HL-60a  6,44 ± 0,17  6,96 ± 0,17  0,52 
HL-60/ADRb  5,17 ± 0,14  7,12 ± 0,04  1,95 
MCF-7a  >5,8  6,75 ± 0.3  <0,85  
MCF-7/ADRb  5,1 ± 0,1  7,15 ± 0,1  2,05 
 
Gong et al. (2003) detected a different intracellular distribution of daunorubicin in 
sensitive and resistant human acute promyeloid leukemia (HL-60) cells. In resistant 
cells, daunorubicin was sequestered into lysosomes whereas in sensitive cells, it was 
more evenly distributed throughout the whole cell. They measured the pH difference 
between lysosomes and cytosol, and detected that pH difference was 0.52 in sensitive 
cells and 1.95 in resistant cells. When abolishing cellular endomembrane pH gradients 
of resistant cells, sequestration of daunorubicin into lysosomes was abolished and 
intracellular distribution was similar with sensitive cells.  
This pH difference results in large differences in intracellular distribution of drugs in 
resistant and sensitive cancer cells. For example concentration of daunorubicin in the 
nucleus of drug sensitive HL-60 cells was approximately 85-fold larger than in resistant 
HL-60 cells (Duvvuri et al. 2005).  
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6.3 Difference in pH of the recycling endosomes 
 
In addition to lysosomes, drugs can accumulate into other acidic compartments in the 
cells, such as recycling endosomes. Altan et al. (1998) measured the pH within the 
recycling endosomes of human MCF-7 breast cancer cells and multidrug resistance 
MCF-7/ADR cells and observed the endosome pH in drug sensitive MCF-7 cells to be 
6.6±0.1 whereas in resistant MCF-7/ADR cells it was 6.1±0.1. That can cause the 
sequestration of weakly basic anticancer drugs to the endosomes and away from their 
site of action. 
 
6.4 Changes in vesicular architecture and localization 
 
The distribution of lysosomes, trans-Golgi network and endosome compartment is 
different in resistant and sensitive cells. Altan et al. (1998) studied the distribution of 
these acidic compartments in human MCF-7 breast cancer cells and multidrug 
resistance MCF-7/ADR cells by labeling with specific fluorescent probes against these 
compartments. The authors observed that in drug sensitive cells these compartments are 
distributed throughout the cytoplasm whereas in resistant cells they are localized to one 
side of the nucleus. That could enhance the redistribution of drug into these vesicles 
away from the nucleus and thus protect the nucleus from anticancer drugs in resistant 
cells (Raghunand et al. 1999). 
Changes in number, volume and membrane area of the endosomes can also alter the 
distribution of drugs in resistant cancer cells. Sehested et al. (1987) found out that 
doxorubicin-resistant murine P388 cells had increased volume (0 vs 4.7-7.8 µm3), 
number (0 vs. 139-205 endosomes/cell) and membrane area (14.1-17.5 vs. 73.6-95.5 
µm2) of the endosome compartment compared to sensitive cells. In sensitive cells, the 
endosomal compartment was so small that median values were below detection limit in 
some cases (zero values), but as can be seen from the original article, the endosomal 
compartment was still present also in sensitive cells. Hurwitz et al. (1997) studied the 
architecture of human U-937 myeloid leukemia cell line and its doxorubicin-selected 
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variant U-A10 and found expanded acidic vesicles belonging to lysosomal compartment 
in resistant cells compared to sensitive cells. In resistant cells, daunorubicin was linearly 
accumulated into these vesicles, whereas in sensitive cells daunorubicin accumulation to 
these vesicles was nonlinear and saturated with larger daunorubicin incubation 
concentrations. Consequently, accumulation into these vesicles in resistant cells with 
larger, but still pharmacologically relevant, incubation concentration (500 ng/mL of 
daunorubicin for 1 hour) was 2-2.5-fold greater than in sensitive cells causing decreased 
concentrations of doxorubicin in the nucleus (Figure 9). 
 
 
Figure 9. Daunorubicin distribution visualized by fluorescence microscopy in U-937 (A, 
B) and U-A10 cells (C, D) (Hurwitz et al. 1997). In drug sensitive cells (A, B) 
daunorubicin is mainly concentrated in the nucleus whereas in resistant cells (C,D) 
daunorubicin is also distributed to expanded acidic vesicles decreasing the 
concentration in the nucleus. 
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Enhanced turnover of acidic vesicles i.e. enhanced endocytosis/exocytosis have been 
observed in resistant cells (Martínez-Zaguilán et al. 1999). The authors observed that 
the release rate of endosomally trapped coumarin-dextran was higher in drug resistant 
MCF-7 cells (about 1.5 % min
-1
) than in parental drug-sensitive cells (about 0.5 % min
-
1
). Consequently, the authors suggested that the reason for drug resistance could be 
enhanced exocytosis of drug out from the cell in addition to its accumulation into acidic 
vesicles. The same group investigated the effect of enhanced turnover on drug 
resistance in cells not overexpressing MDR1 by modeling drug partition between four 
compartments: extracellular medium, cytosol, perinuclear region and nucleus, and 
ensomal/exocytotic vesicles (Raghunand et al. 1999). They named three major 
parameters reducing perinuclear concentrations in resistant cells to be low endosomal 
pH, high endosomal turnover rate and active transport of drug into endosomes. In their 
model both active transport of drug into endosomes by e.g. organic cation/H
+
 antiporter 
and high endosomal turnover rate were required to lower the perinuclear concentration 
enough to have a therapeutic relevance, either of them alone was not sufficient to do so. 
Also, the relevance was seen only when MDR1 was not considered i.e in resistant cells 
not overexpressing MDR1. 
Enhanced turnover of acidic vesicles was also observed by Seidel et al. (1995), who 
studied the intracellular pathway of daunorubicin by fluorescence microscopy in 
resistant and sensitive human gastric carcinoma cells EPG85. The authors observed the 
formation of fluorescent vesicles in resistant cells, starting from the perinuclear region 
after 6 hours incubation. Daunorubicin was increasingly concentrated into these vesicles 
and the amount in nucleus was decreased to a baseline after 48 h. Vesicles were moved 
from the perinuclear region to the cell periphery. 
 
6.5 Increase in transporter expression 
 
Different protein expression of drug sensitive and resistant cancer cell lines can also 
cause variation in distribution of drugs (Duvvuri, Krise 2005). Many efflux proteins 
such as MDR1, MRP1 and breast cancer resistance protein (BCRP) are overexpressed 
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in resistant cancer cell lines and decrease intracellular concentrations of their substrates. 
But as mentioned earlier, it is questionable if these transporters have a role in 
intracellular sequestration of drugs. Another protein suggested to participate in drug 
distribution in resistant cancer cell lines is lung resistance-associated protein (LRP) 
(Meschini et al. 2002), but more studies are needed to confirm its role.  
Perhaps most widely studied efflux transporters are MDR1 and MRP1. MDR1 and 
MRP1 are located in the plasma membrane of cells, where they pump drugs out from 
the cell, thus decreasing intracellular concentrations. MDR1 binds its substrates from 
the inner leaflet of plasma membrane, whereas MRP1 binds its substrates from the 
cytoplasm (Larsen et al. 2000).  
Efflux transporters are also found in vesicular membranes of resistant cancer cells, 
where they may have a role in pumping drugs from the cytosol to the vesicles and thus 
increasing the drug accumulation into vesicles (Van Luyn et al. 1998). The authors 
studied microscopically the localization of the MRP1 protein in human small cell lung 
carcinoma (GLC4) cell line as well as in its multidrug resistant subline GLC4-ADR. 
MRP1 expression was slightly positive in plasma membrane of GLC4-cells and strongly 
positive in plasma membrane of GLC4-ADR-cells. Expression was positive also in 
dense spots near the nucleus in GLC4-ADR-cells. Highly water-soluble glutathione 
conjugate known to be transported by MRP1 was found inside these vesicles in resistant 
cells which led the authors to conclusion that MRP1 is active also inside cell in the 
membrane of these vesicles. Also doxorubicin, known to be transported by MRP1, 
accumulated into these vesicles in the GLC4-ADR-cells.  
Another study concerning intracellular MRP1 was conducted by Gong et al. (2003), 
who, in addition to studying daunorubicin distribution in sensitive and resistant HL-60 
cells, studied also another compound, sulforhodamine101 (SR101), which was noticed 
to sequester into the Golgi apparatus in resistant cells. Unlike with daunorubicin, 
disruption of pH difference in cellular endomembranes did not alter the distribution of 
SR101 in resistant cells and authors suggested alternative mechanism for sequestration 
to be transport proteins. Overexpression of MRP1 was detected in resistant cells 
compared to sensitive cells and MRP1 was localized to the Golgi apparatus using 
immunofluorescence protocol. When preincubating resistant cells with MRP1 inhibitor, 
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sequestration of SR101 into the Golgi apparatus was abolished. MRP1 inhibitor didn’t 
have an effect to daunorubicin distribution and expression of MDR1 in both cells was 
negligible.  
Also MDR1 has been detected in intracellular sites of multidrug resistant cells. 
Meschini et al. (2000) observed that cyclosporine A, a known MDR1 modulator, 
significantly increased doxorubicin accumulation into resistant human colon 
adenocarcinoma (Lovo 7) cells (mean fluorescence channel was about 25 units larger 
with cyclosporine A than without it). Lovo 7 cells do not express MDR1, or two other 
major efflux proteins (LRP or MRP1), in their cell membrane but intracellular MDR1 
was demonstrated. Intracellular MDR1 could sequester doxorubicin away from the 
nucleus in resistant cells and inhibition of MDR1 by e.g. cyclosporine A could improve 
doxorubicin performance in anticancer therapy.  
However, there are also opposite results about the activity and existence of intracellular 
transporter proteins and these seem to be dependent on the cell line in question. For 
example human ovarian carcinoma (A2780) and its multidrug resistant subline 
A2780AD did not express MRP1 in their plasma membranes or intracellular 
compartments (Van Luyn et al. 1998). With human U-937 myeloid leukemia cell line 
and its doxorubicin-selected variant U-A10, MDR1 and MRP was colocalized with 
plasma membrane, but not lysosomes or other intracellular compartments (Hurwitz et al. 
1997). Even if these transporters are found in intracellular compartments, it is 
challenging to prove whether they are active there or just on their way to the plasma 
membrane after synthesis.  
There is also some speculation that the overexpression of ABC transporters may affect 
the pH of the intracellular compartments, which affects the sequestration of drugs into 
these compartments (Larsen et al. 2000). However, the evidence for that is still quite 
scarce. 
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7 CONCLUSIONS 
 
Although many of the examples discussed in this literature review concern anticancer 
drug therapy, intracellular distribution is important to consider with other drugs also. It 
affects the efficacy of the drug, it can explain the side-effects and the knowledge of the 
intracellular sequestration mechanisms can be utilized when designing new drugs. The 
importance amplifies especially with potent drugs having narrow therapeutic window, 
since even small changes in concentrations can have a large effect on the response to the 
drug therapy.  New methods available for studying intracellular drug distribution have 
expanded our understanding about it, but there is still work to do in the development of 
isolation and purification methods for organelles. Intracellular sequestration of drugs 
can also partly explain multidrug resistance in cancer drug therapy and knowledge of 
the mechanisms can be utilized when designing strategies to overcome the resistance. 
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1 INTRODUCTION 
 
Knowledge of the intracellular distribution of drugs is necessary to predict the effect of 
drugs on intracellular targets. Also drug clearance and transporter binding sites are often 
intracellular. In many cases, total plasma concentrations are used to predict the 
disposition and function of the drug, which can lead to false conclusions. Knowing the 
unbound concentration in the site of action would greatly improve correlation between 
in vitro experiments and in vivo parameters (in vitro-in vivo correlation, IVIVC). 
Intracellular distribution of small molecule drugs is not commonly studied (Duvvuri, 
Krise 2005). Perhaps the most frequently used methods are those based on fluorescent 
microscopy so the knowledge of intracellular distribution is somewhat restricted to 
fluorescent compounds (Duvvuri et al. 2004). However, the importance of the 
intracellular concentration of drugs is recognized and new experimental and 
computational methods for studying it are being developed. 
The multidrug resistance 1 (MDR1) transporter (ABCB1, P-glycoprotein) is a member 
of the ABC transporter family. It uses energy from ATP hydrolysis to export substrates 
out of the cell through the apical plasma membrane of the cell (Alberts 2002b). MDR1 
is expressed in the small intestine, blood-brain barrier, liver and kidneys and it exports a 
wide selection of usually hydrophobic and cationic molecules out of the cells 
(Giacomini et al. 2010). Expression and functionality of MDR1 is susceptible to 
induction and inhibition which can affect ADME-properties of MDR1 substrates and 
cause drug-drug interactions. Passive diffusion through the plasma membrane has to be 
taken into account since it affects the clinical significance of these changes.  
The main mechanism of MDR1 efflux is most likely influx hindrance in which the 
substrate partitions into the plasma membrane and binds directly to MDR1 without 
partitioning into intracellular fluids (Raub 2006). Therefore unbound concentration of 
MDR1 substrate in the binding site (plasma membrane) is useful to know in order to 
better predict the role of active transport in overall transport process. Many models for 
MDR1 function and substrate binding have been suggested but two of them are more 
studied than others: hydrophobic vacuum cleaner - and flippase model. In both of them 
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the binding of substrates takes place in the inner leaflet of the plasma membrane and 
thus substrates have to first partition into the lipid bilayer in order to interact with 
transporter (Hennessy, Spiers 2007).  
Three compounds were used in our experiments: celiprolol, clotrimazole and 5(6)-
carboxy-2',7'-dichlorofluorescein (CDCF). The drugs selected have different 
lipophilicities, and celiprolol and CDCF are known MDR1 substrates.  
 
 
2 AIMS OF THE STUDY 
 
The goal of this work is to study partitioning of celiprolol, clotrimazole and CDCF 
between plasma membrane and cytoplasm in vitro in MDCKII-wt and MDCKII-MDR1 
cells. The aims of the study were to (1) validate the isolation protocol for plasma 
membrane and cytoplasm and (2) measure the concentrations of three drugs selected in 
plasma membrane, cytoplasm and cell lysate.  
Isolation of plasma membrane is done by a fractionation protocol based on different 
centrifugation speeds to pellet different cellular compartments. The concentrations of 
drugs are measured in these cell compartments and in cell lysate after validation of the 
protocol. Experiments with MDCKII-MDR1 cells are done with and without MDR1-
inhibitor verapamil. Kinetics of the partitioning of CDCF to the plasma membrane is 
also studied. Vesicle assay is done for clotrimazole to study if it is a MDR1 substrate 
and/or inhibitor. The drugs selected have different lipophilicity (different log P or log D) 
and celiprolol and CDCF are known substrates of efflux transporter MDR1.  
Considering the drug uptake experiments, the hypothesis was that the concentration in 
wild type cells is similar as in MDR1 transfected cells when inhibiting MDR1 efflux by 
verapamil. Also, according to the hypothesis, concentrations in plasma membrane of 
MDCKII-MDR1 cells should be smaller than in wild type cells if the drug is a MDR1 
substrate. Partition of drugs to cellular fractions was also compared within cell types to 
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see if partitioning was similar in smaller and higher concentrations or is it e.g. saturable. 
Finally, Km (or Ki for clotrimazole) concentrations from literature were used to 
determine the corresponding concentration in plasma membrane, Km(membrane), which 
could be more useful in predicting transporter contribution to transport process and not 
that prone to variation between different experimental design.  
 
 
3 MATERIALS AND METHODS 
 
3.1 Test compounds 
 
Celiprolol is beta-blocking agent used in the treatment of high blood pressure and 
coronary artery disease. It blocks selectively beta-1-receptors. The usual dose is 200 mg 
and it can be doubled to 400 mg if needed. It is mainly (95 %) excreted unchanged 
through kidneys and bile and only about 25 % is bound to plasma proteins. Half-life of 
celiprolol is 5-8 h. It is actively excreted back to intestines after oral absorption and 
bioavailability increases when dose is increased. It is available with multiple brand 
names in Europe, e.g. Selectol and Celiprolol Vitabalans (Duodecim Oy 2013). 
Physicochemical parameters of celiprolol are presented in Table 1. Celiprolol is a 
substrate of MDR1 with Km value of 1 mM and Vmax, of 113 ± 11 pmol/10
6
 cells/ min 
(Karlsson et al. 1993). It is also suggested to be a substrate of organic anion transporting 
polypeptide (OATP-1A2) influx transporter (Kato et al. 2009).  
Clotrimazole is a broad-spectrum antifungal medicine used in local treatment of vaginal 
yeast infection as a cream (10-20 mg/g) or vaginal tablets (200 or 500 mg). It can also 
be used to treat yeast infections in the skin or mouth. It inhibits ergosterol synthesis of 
the yeast. Only 3-10 % is absorbed systemically after local treatment. Clotrimazole 
undergoes hepatic metabolism and inhibits CYP3A4 and CYP2C9 enzymes which can 
cause drug-drug interactions (Duodecim Oy 2013). Clotrimazole is poorly absorbed 
orally and has a half-life of 2 h. Clotrimazole is available as a cream or vaginal tablets 
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with brand name Canesten in Europe. In US Clotrimazole is available as oral topical 
tablets with the brand name Mycelex Troche and as topical preparation with brand 
names Lotrimin, Gyne-Lotrimin, Canesten and Mycelex (Drugsite Trust 2013). 
Physicochemical parameters of clotrimazole are presented in Table 1. Clotrimazole is 
an inhibitor of MDR1 with Ki value of 44 µM (Yasuda et al. 2002).  It may also have an 
influence on multidrug resistance proteins 1 and 2 (MRP1 and MRP2) (Wishart 
research group, 2013).  
5(6)-Carboxy-2',7'-dichlorofluorescein (CDCF) is a fluorescent compound extensively 
used in research. The hydrolyzed form of CDCF can pass the cell membrane by active 
efflux mediated by MRP2, MRP3, MRP5, and perhaps also by MRP1 (Vellonen et al. 
2010). It has also proven to be MDR1 substrate in membrane vesicle assay, with Km of 
2.73 µM and Vmax of 1.97 pmol/min/mg tot.prot. (results from Sf9-MDR1 membrane 
vesicle assay, Nora Sjöstedt, personal communication). Physicochemical parameters of 
CDCF are presented in Table 1. 
Verapamil is a calcium-channel blocker used as anti-arrhythmia agent. It is commonly 
used as an inhibitor of MDR1 in experiments and its IC50 values are 10.7-33.5 µM 
depending on the substrate used (Rautio et al. 2006) and Ki value is 15.1 µM (Tang et al. 
2002).  Commonly used verapamil concentration in inhibitor experiments is 200 µM.  
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Table 1. Physicochemical parameters of test drugs and their interaction with MDR1. 
Physicochemical parameters for clotrimazole, celiprolol and CDCF 
  clotrimazole celiprolol (HCl) CDCF 
Molecular mass (g/mol)1 344.84 415.95 445.21 
log P 1 5.4 1.9 2.6 
log D (pH 7.4) 1 5.4 0.1 -0.5 
pKa 6.6 2 9.7 3 5.1 4 
  
MDR1 substrate - yes5 yes7 
Km (µM) - 1000 5 3 7 
MDR1 inhibitor yes6  -  - 
Ki (µM) 44 6  -  - 
1 
Royal Society of Chemistry, 2013,calculated by ACDlabs 
2 
Wishart research group,
 
2013 
   3 Pharma Professional Services, 2013 
  4 Sigma-aldrich, 2013 
   5 Karlsson et al. 1993 
   6 Yasuda, Lan et al. 2002  
 
  7 Results from Sf9-MDR1 membrane vesicle assay, Nora Sjöstedt, personal communication 
 
3.2 Materials 
 
Materials used in cell culturing were Dulbecco’s modified eagles medium D-MEM (low 
glucose (1 g/l D-glucose), L-glutamine, pyruvate, Gibco, 31885-023), Fetal bovine 
serum and Penicillin-Streptomycin antibiotic solution (10 000 IU/ml penicillin, 10 000 
µg/ml streptomycin, Gibco, 15140-122). Washing solution was Dulbecco’s phosphate 
buffered saline (DPBS, - CaCl, -MgCl2, Gibco 14200-067). The solution used to detach 
the adherent cells was 0.5% trypsin-EDTA (Gibco, 15400-054) or Tryple express 
(Gibco 12604-021).   
Celiprolol hycdrochloride was supplied by Santa Cruz Biotech (USA), clotrimazole by 
MP Biomedicals (France), and 5(6)-Carboxy-2',7'-dichlorofluorescein (CDCF) and 
verapamil were supplied by Sigma Aldrich (USA). Stock solutions were made in 
dimethyl sulfoxide (DMSO, Sigma Aldrich, France) and stored at -20 ºC. Stock 
solutions were diluted with DMSO and added to buffer in order to get the desired 
concentration in the experiments. Buffer used was Hanks’ Balanced Salt Solution 
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(HBSS, 14025-050, Gibco) supplemented with 10 mM Hepes. Final concentration of 
DMSO in experiments was 2 % of the total reaction volume (v/v).   
 
3.3 Cell culture 
 
Madin-Darby canine kidney II wild type (MDCKII-wt) renal epithelial cells were 
received from University of Tokyo. Madin-Darby canine kidney II cells expressing 
human MDR1 (MDCKII-MDR1) cells were received from Netherlands Cancer Institute.  
The growth medium used was D-MEM supplemented with 10 % fetal bovine serum and 
1 % penicillin-streptomycin antibiotic solution. MDCKII-wt and MDCKII-MDR1 cells 
were split twice a week by washing the confluent cell monolayer with DPBS, detaching 
the cells by incubating with 0.5% trypsin-EDTA for 5 minutes at 37 °C and splitting 1:9. 
Cells were kept at 37 °C in 5 % CO2. 
Working stocks of both MDCKII-wt and MDCKII-MDR1 cells were cryopreserved in 
liquid nitrogen which enabled the use of cells with similar passage numbers in all the 
drug uptake experiments. Freezing medium used was growth medium supplemented 
with 10 % DMSO and 50 % Fetal bovine Serum. Cells were first kept in isopropyl 
alcohol container at -80 °C overnight and then placed to liquid nitrogen until use.  
Successful freezing was ensured microscopically. Passage numbers used in drug uptake 
experiments were 30-33 for wild type cells and 11-16 for MDR1-transfected cells. 
Passage number of cells used in validation of isolation protocol was 30 and validation 
was done with wild type cells. 
 
3.4 Validation of isolation protocol 
 
Isolation protocol used in these experiments is based on different sedimentation rate of 
cell organelles at different centrifugal force, and the main interest was to isolate the 
plasma membrane and cytoplasm. The protocol is described in Appendix 1. Shortly, 
MDCKII-wt cells were harvested, homogenized and centrifuged at different centrifugal 
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forces. Centrifugation steps are described in Figure 1. Four samples were collected: 
sample A containing cell lysate; sample B mitochondria, peroxisomes and lysosomes; 
sample C plasma membrane and sample D cytoplasm. Determination of the protein 
concentration in samples was done by Bio-Rad protein assay to evaluate the need for 
sample dilution to SDS-page. Bio-Rad protein assay is based on a color change of a dye 
Coomassie blue (Bio-Rad laboratories, Finland, 500-0006) in response to different 
protein concentrations. Visual quantification showed that the protein concentration in 
sample A was larger than in other samples, so sample A was diluted 1:2 with milliQ 
water prior to SDS-page.  
 
 
Figure 1. Isolation protocol for plasma membrane and cytoplasm. In validation of 
protocol samples A-D were collected. When studying drug distribution, only samples A, 
C and D were collected. 
 
Western Blot was done to validate the protocol. Proteins were separated according to 
their molecular weights on 10 % SDS-polyacrylamide gel (456-1033, Bio-Rad 
Laboratories, USA) and electroblotted onto a nitrocellulose membrane (162-0145, Bio-
Rad Laboratories, Germany) to which antibodies were added. Primary antibodies were 
anti UGP2 (Aviva systems biology, San Diego, ARP48303_P050) as a marker of 
cytoplasm, anti G6PC (Aviva systems biology, San Diego, ARP44224_P050) as a 
marker of endoplasmic reticulum, anti-COX (antibodies-online.com, Germany, 
ABIN401531) as a marker of mitochondria and anti CD73 (antibodies-online.com, 
Germany, ABIN739353) as a marker of plasma membrane. Secondary antibody was 
Anti-Goat (Millipore, USA, AP106P) against anti-COX and Anti-Rabbit (Millipore, 
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USA, AP307P) against the other antibodies. Used antibody dilutions were 1:1000 for all 
primary antibodies, 1:5000 for Anti-Goat secondary antibody and 1:2000 for Anti-
Rabbit secondary antibody. UGP2 (UDP-glucose pyrophosphorylase 2) is an enzyme 
involved in mammalian carbohydrate inter-conversions with molecular weight of 57 
kDa. G6PC (glucose-6-phosphatase, catalytic subunit) is an enzyme functioning in 
gluconeogenesis and glycogenolysis in endoplasmic reticulum with molecular weight of 
41 kDa. COX (cytochrome c-oxidase) is an enzyme involved in mitochondrial electron 
transport chain with molecular weight of 17 kDa. CD73 (5’-nucleotidase, ecto, NT5E) 
is an enzyme which catalyses the conversion of extracellular nucleotides to membrane-
permeable nucleosides in plasma membrane, with molecular weight of 65 kDa. Low 
protein marker (Prestained SDS-PAGE standards, 161-0305, Bio-Rad Laboratories, 
USA), containing six proteins with known molecular weights, was used to estimate the 
size of the proteins in samples A-D (Figure 2).  Detection was done with ECL detection 
system (GE Healthcare Amersham, Germany, ECL Western Blotting Detection reagents, 
RPN 2106) and films were exposed 30 min.  
 
Figure 2. Low protein marker including six reference bands with known molecular 
weights 
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3.5 Analysis method  
 
CDCF concentrations in isolated cell fractions were measured with Varioskan Flash 
spectrofluorometer (Thermo Scientific, Finland) using excitation and emission 
wavelengths 510 nm and 535 nm, respectively. Standard curve to calculate 
concentrations is presented in Appendix 2. Celiprolol and clotrimazole concentrations 
were measured using UPLC-MS technique. ULPC (Acquity, Waters, USA) column 
used was UPLC HSS T3 with dimension 2.1 x 100 mm and particle size 1.8 µm (Waters, 
USA). Flow rate was 0.3 ml/min and injection volume 0.5 µl. Mass spectrometry used 
was triple quadrupole mass spectrometer (Waters TQ-S, Waters, USA) with 
electrospray ionization on positive mode. Propranolol was used as an internal standard. 
Prior to analysis, samples were centrifuged at 9600 g for 5 min and 25 µl internal 
standard (propranolol 0.25 mg/ml) was added to 100 µl of supernatant. 
  
3.6 Uptake kinetics of CDCF 
 
Different incubation times were tested to see how long it takes for CDCF to achieve 
steady state in MDCK-MDR1 cell lysates and whether verapamil as an MDR1 inhibitor 
affects that time or not. Incubation times were 1, 5, 10, 30, 60, 90 and 120 minutes for 
CDCF 100 µM and 5, 10, 30, 60 and 90 minutes for CDCF 100 µM with verapamil 200 
µM. Since the interest was only to evaluate uptake kinetics of drugs, the whole isolation 
protocol was not done, instead only sample A was collected.  
 
3.7 Vesicle study for clotrimazole 
 
Vesicle study was done to determine if clotrimazole is a substrate and/or an inhibitor of 
MDR1. The use of inside-out vesicles enables the measurement of drug uptake into 
vesicles and evaluation of the effect of efflux transporter MDR1 in the overall transport 
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process. Since MDR1 uses energy from ATP to transport its substrates, the efflux does 
not work in the absence of ATP. 
Vesicle assay steps and plate setup are described in detail in Appendix 3. In the 
substrate test, inside-out vesicles prepared from MDR1-transfected Spodoptera 
frugiperda (Sf9) insect cells were incubated in 96-well plate with clotrimazole 1, 10 and 
100 µM in the presence and absence of ATP. In the inhibitor test, CDCF, a known 
substrate of MDR1, was incubated with vesicles with clotrimazole 5 µM, clotrimazole 
50 µM and control (DMSO) to see if clotrimazole inhibits the transport of CDCF by 
MDR1. Uptake of clotrimazole to the vesicles was measured by mass spectrometry and 
uptake of CDCF by spectrofluorometer.  
 
3.8 Drug uptake experiments 
 
Experiments were done with MDCKII-wt cells and MDCKII-MDR1 cells. All the 
experiments were done in duplicates and some of them were repeated in order to see if 
there is day-to-day variation in experiments. Concentrations of drugs were 30 µM, 100 
µM and 200 µM for CDCF and clotrimazole and 100 µM, 300 µM and 500 µM for 
celiprolol. MDCKII-MDR1 cell experiments were done in the presence and absence of 
MDR1 inhibitor verapamil 200 µM. The concentration of DMSO was kept under 2 % in 
order not to harm cells.  
Culture media from MDCKII-wt or MDCKII-MDR1 cells was first removed and cells 
were washed with 5 ml HBSS/Hepes 10 mM solution and incubated with 5 ml of 
HBSS/Hepes for 10 minutes at 37 °C. Drugs in DMSO were added to HBSS/Hepes 
solution and incubated with cells for 60 minutes at 37 °C with agitation.  
After 60 minutes incubation, reaction was stopped by removing drug-buffer solution 
and by washing cells three times with 10 ml of ice cold PBS. Isolation of cell organelles 
was done as previously described (Appendix 1, Figure 1), except that sample B, 
containing mitochondria, was not collected since the interest was to measure 
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concentrations in plasma membrane and cytoplasm. The experiments after drug 
incubation were done on ice and centrifugations at 4 °C. 
 
3.9 Data analysis 
 
Cell count was done by Cedex XS (Switzerland) using Cedex Smart Slides 
(05650801001, Roche, Germany). Cells were stained with Tryptan Blue Stain (0.4 %) 
(Gibco, USA, 15250-061) and the amount and diameter of cells were measured before 
and after homogenization of cells.  
Concentrations of test drug in lysate, plasma membrane and cytoplasm were calculated 
with equation 
                      Equation 1 
, where c1 is concentration of test drug in certain fraction (lysate, plasma membrane or 
cytoplasm), V1 is volume of that fraction, c2 is measured concentration of test drug 
gained from mass spectrometry or spectrofluorometer and V2 is the volume from which 
the sample was taken.  
When calculating lysate concentration, volume of cell lysate V1, can be calculated 
knowing the amount (n) and radius of cells (r) before homogenization (V1= n 
 
 
 πr3) and 
V2 is the volume of cell homogenate (5 ml).  
When calculating plasma membrane concentration, volume of plasma membrane V1, 
can be calculated knowing the amount of broken cells (nbroken), radius of the cells (r) and 
thickness of plasma membrane (d=4.7 nm) in MDCK cells (Lärmer et al. 1997). V1= 
nbroken x ( 
 
 
 πr3 -  
 
 
 π(r-d)3). V2 is the volume to which the plasma membrane pellet has 
been resuspended (200 µl).  
When calculating cytoplasm concentration, volume of cytoplasm V1, can be calculated 
knowing the amount of broken cells (nbroken), radius of the cells and knowing that 
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cytoplasm occupies 54 % of the total cell volume (Alberts 2002a). V1= 0.54 x nbroken  
 
 
 
πr3. V2 is the volume of supernatant after last centrifugation (5 ml).  
Km(membrane) for CDCF and celiprolol and Ki(membrane) for clotrimazole is 
determined as the concentration in plasma membrane of MDCKII-MDR1 cells without 
verapamil when incubation concentration is set to be Km (or Ki) value of the compound.  
 
 
4 RESULTS 
 
4.1 Validation of isolation protocol 
 
Four gels were prepared for four primary antibodies: (1) anti UGP2 (marker of 
cytoplasm), (2) anti G6PC (marker of endoplasmic reticulum), (3) anti-COX (marker of 
mitochondria) and (4) anti CD73 (marker of plasma membrane). With anti-COX, there 
were some technical problems due to e.g. unspecific binding and blotting was 
unsuccessful with that antibody. Films from gels 1, 2 and 4 along with clarifying drafts 
are presented in Figure 3, Figure 4 and Figure 5, respectively. 
Film from anti UGP2 (Figure 3) shows that antibody identifies cytoplasmic markers in 
sample A (lysate) and sample D (cytoplasm). Molecular weights of the identified 
proteins are approximately 34.3 kDa and 20.7 kDa in lysate, and 34.3 kDa in cytoplasm 
and there are several bands in both of the samples. Molecular weight of the UGP2 
protein is 57 kDa.  
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Figure 3. Anti UGP2 antibody identifies cytoplasmic markers in samples A and D. 
 
Film from anti G6PC (Figure 4) shows that antibody identifies endoplasmic reticulum 
markers in sample A (lysate) and sample C (plasma membrane). Molecular weights of 
the identified proteins are approximately 23 kDa in lysate (several bands) and 90 kDa in 
plasma membrane. Molecular weight of the G6PC is 41 kDa. 
 
Figure 4. Anti G6PC antibody identifies endoplasmic reticulum markers in samples A 
and C. 
 
Film from anti CD73 (Figure 5) shows that antibody identifies plasma membrane 
markers in sample A (lysate), sample C (plasma membrane) and sample D (cytoplasm). 
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Molecular weights of the identified proteins are 34.3 kDa and less than 20.7 kDa in 
lysate and plasma membrane, and less than 20.7 kDa in cytoplasm. There are several 
bands in all of the three samples. Molecular weight of CD73 is 65 kDa.  
 
Figure 5. Anti CD73 antibody identifies plasma membrane markers in samples A, C and 
D. 
 
4.2 Uptake kinetics of CDCF 
 
Concentration of CDCF with incubation concentration 100 µM in MDCKII-MDR1 cell 
lysate after different incubation times is presented in Figure 6. The experiments were 
done with and without MDR1 inhibitor verapamil 200 µM.  
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Figure 6. Average concentration of CDCF in cell lysate ± standard deviation after 
different incubation times (n=2). 
 
4.3 Vesicle study for clotrimazole 
 
Average concentrations of clotrimazole (substrate study) and average fluorescence of 
CDCF (inhibitor study) in vesicles in the presence and absence of ATP are presented in 
Figure 7 and Figure 8. 
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Figure 7. Average concentration of clotrimazole in vesicles ± standard deviation after 
different incubation concentrations with and without ATP (n=3). 
 
 
Figure 8. Average fluorescence of CDCF in vesicles ± standard deviation when 
incubating with clotrimazole or control with and without ATP (n=3). 
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4.4 Drug uptake experiments 
 
Concentrations of the drugs tested in lysate, plasma membrane and cytoplasm of 
MDCKII-MDR1 cells with and without verapamil and in MDCKII-wt cells are 
presented in Appendix 4. 
 
4.4.1 CDCF 
 
Concentrations of CDCF in lysate, plasma membrane and cytoplasm fractions of 
MDCKII-MDR1 cells with and without verapamil and in MDCKII-wt cells with 
incubation concentrations 30, 100 and 200 µM are presented in Figure 9-Figure 11.  
 
 
Figure 9. Mean concentrations ± standard deviation (n=2) of CDCF in lysate, plasma 
membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil and in 
MDCKII-wt cells when incubation concentrations of CDCF is 30 µM.  
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Figure 10. Mean concentrations ± standard deviation (n=2) of CDCF in lysate, plasma 
membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil and in 
MDCKII-wt cells when incubation concentrations of CDCF is 100 µM. 
 
 
Figure 11. Mean concentrations ± standard deviation (n=2) of CDCF in lysate, plasma 
membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil and in 
MDCKII-wt cells when incubation concentrations of CDCF is 200 µM.  
 
Uptake profiles of CDCF in MDCKII-MDR1 cells with and without verapamil and in 
MDCKII-wt cells are presented in Figure 12. Shown are concentrations in plasma 
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membrane, cytoplasm and lysate (Cfraction) when incubation concentration is increased 
from 30 to 200 µM.  
  
  
Figure 12. Uptake profile of CDCF. Mean concentration ± standard deviation (n=2) of 
CDCF in the fractions (Cfraction) after different incubation concentrations in MDR1 
transfected cells with and without verapamil and in wild type cells.  
 
Determination of the Km(membrane) value can be done by determining the 
concentration in the plasma membrane of MDR1 cells when extracellular concentration 
is  Km (3 µM for CDCF). With the drug uptake experiments, the extracellular 
concentration is assumed to be approximately the same as the incubation concentration 
and the Km(membrane) can be determined from the uptake profile. This requires data to 
be extrapolated, since the incubation concentration as low as 3 µM could not be tested 
because of detection limits. Value for Km(membrane) calculated from this extrapolated 
curve is 0.3 µM (data not shown).  
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4.4.2 Clotrimazole 
 
Concentrations of clotrimazole in lysate, plasma membrane and cytoplasm fractions of 
MDCKII-MDR1 cells with and without verapamil and in MDCKII-wt cells with 
incubation concentrations 30, 100 and 200 µM are presented in Figure 13-Figure 15.  
 
 
Figure 13. Mean concentrations ± standard deviation (n=2) of clotrimazole in lysate, 
plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil 
and in MDCKII-wt cells when incubation concentrations of clotrimazole is 30 µM. 
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Figure 14. Mean concentrations ± standard deviation (n=2) of clotrimazole in lysate, 
plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil 
and in MDCKII-wt cells when incubation concentrations of clotrimazole is 100 µM. 
 
Figure 15. Mean concentrations ± standard deviation (n=2) of clotrimazole in lysate, 
plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without verapamil 
and in MDCKII-wt cells when incubation concentrations of clotrimazole is 200 µM. 
Uptake profiles of clotrimazole in MDCKII-MDR1 cells with and without verapamil 
and in MDCKII-wt cells are presented in Figure 16. Shown are concentrations in 
plasma membrane, cytoplasm and lysate (Cfraction) when incubation concentration is 
increased from 30 to 200 µM.  
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Figure 16. Uptake profile of clotrimazole. Mean concentration ± standard deviation 
(n=2) of clotrimazole in the fractions (y-axis) after different incubation concentrations 
(x-axis) in MDR1 transfected cells with and without verapamil and in wild type cells.   
 
Inhibitory affinity of clotrimazole to MDR1 is Ki=44 µM, so Ki(membrane) value for 
clotrimazole in plasma membrane of MDR1 cells can be determined from the Figure 16. 
By definition, Ki(membrane) is the corresponding concentration in plasma membrane, 
when incubation concentration is 44 µM, so Ki(membrane)=597 µM. 
 
4.4.3 Celiprolol 
 
Concentrations of celiprolol in lysate, plasma membrane and cytoplasm fractions of 
MDCKII-MDR1 cells with and without verapamil and in MDCKII-wt cells with 
incubation concentrations 100 and 300 and 500 µM are presented in Figure 17-Figure 
19.  
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Figure 17. Logarithm of mean concentrations ± standard deviation (n=2) of celiprolol in 
lysate, plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without 
verapamil and in MDCKII-wt cells when incubation concentrations of celiprolol is 100 
µM. (* value extrapolated from calibration curve) 
 
 
Figure 18. Logarithm of mean concentrations ± standard deviation (n=2) of celiprolol in 
lysate, plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without 
verapamil and in MDCKII-wt cells when incubation concentrations of celiprolol is 300 
µM. (*value extrapolated from calibration curve) 
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Figure 19. Logarithm of mean concentrations ± standard deviation (n=2) of celiprolol in 
lysate, plasma membrane and cytoplasm of MDCKII-MDR1 cells with and without 
verapamil and in MDCKII-wt cells when incubation concentrations of celiprolol is 500 
µM. 
 
Uptake profiles of celiprolol in MDCKII-MDR1 cells with and without verapamil and 
in MDCKII-wt cells are presented in Figure 20. Shown are concentrations in plasma 
membrane, cytoplasm and lysate (Cfraction) when incubation concentration is increased 
from 100 to 500 µM.  
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Figure 20. Uptake profile of celiprolol. Mean concentration ± standard deviation (n=2) 
of celiprolol in the fractions (y-axis) after different incubation concentrations (x-axis) in 
MDR1 transfected cells with and without verapamil and in wild type cells.   
 
Determination of the Km(membrane) value for celiprolol in plasma membrane of MDR1 
cells when incubation concentration is Km=1 mM, requires data to be extrapolated. 
Value for Km(membrane) calculated from this extrapolated curve is 77 µM (data not 
shown).  
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5 DISCUSSION 
 
5.1 Validation of isolation protocol 
 
Immunoblotting with mitochondrial antibody was not successful. There were some 
technical problems due to e.g. unspecific binding. Secondary antibody from different 
batch was also tested but despite several attempts made, the immunoblotting was not 
successful. Validation of isolation protocol showed that in sample A (lysate) markers  
from cytoplasm, endoplasmic reticulum and plasma membrane was identified by 
antibodies, which is expected since lysate contains the broken cells and so all organelles 
of the cells should be found in that fraction. In sample B (mitochondria) no markers 
were identified and since immunoblotting was not successful with mitochondrial 
antibody, the content of the sample B remains to be confirmed. In sample C (plasma 
membrane) antibody identified plasma membrane and endoplasmic reticulum markers. 
In sample D (cytoplasm) markers from cytoplasm were identified as well as some weak 
bands from plasma membrane markers. Since the bands from the plasma membrane 
markers (gel 4) were stronger in lysate and plasma membrane, and all the other 
antibodies were found in their designated samples, it can be assumed that separation of 
the plasma membrane and cytoplasm was successful. The molecular weights of the 
identified proteins deviate from the ones expected. However, this is not uncommon and 
the reason could be e.g. degradation of the proteins by proteases, since protease 
inhibitors were not added. Antibody may also bind to other proteins in samples which 
can explain the different size of the proteins identified. Degradation and/or different 
glycosylation can also explain several bands shown in gels.  
 
5.2 Uptake kinetics of CDCF 
 
Uptake kinetics studies reveal that concentration in MDCKII-MDR1 cell lysates is 
increasing up to 90 minutes and after that the steady state seems to be achieved. 
Increase is linear up to 60 minutes and from 60 to 90 minutes, the concentration in cell 
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lysate is increased more strongly. The reason for this strong increase could be e.g. 
deterioration of cells. There seems to be no distinction between incubation with CDCF 
alone or with verapamil. Longer times were not studied since it cannot be confirmed 
that the cells maintain their functionality after long incubations without their growth 
medium and consequently the reliability of the results would deteriorate. The initial 
purpose of the uptake kinetics studies was to evaluate the incubation time needed after 
which steady state would be reached. Since necessary incubation time to achieve steady 
state might cause the cells to deteriorate, we ended up for 60 minutes incubation time, 
which should be short enough for the cells not to weaken and still long enough to 
achieve the concentrations in the fractions high enough to analyze.  
 
5.3 Vesicle study for clotrimazole 
 
Considering standard deviations, there is no difference in clotrimazole uptake into 
vesicles with and without ATP (Figure 7). Based on that it appears that clotrimazole is 
not a MDR1 substrate. However, since clotrimazole has high lipophilicity (log D (7.4) 
=4.9), it can permeate through vesicle membrane easily and passive diffusion has a 
large role in the permeation process. So even if it was a substrate of MDR1, the 
transporter should function very effectively to overcome passive diffusion. Inhibitor test 
reveals that clotrimazole lowers the concentration of CDCF in vesicles in the presence 
of ATP, whereas in the absence of ATP similar lowering does not occur (Figure 8). 
Consequently, it can be deduced that clotrimazole is an inhibitor of MDR1.  
There has been some disagreement whether clotrimazole is a MDR1 substrate or not 
(Takano et al. 2006, Xue et al. 2004, Crivori et al. 2006). Possible interaction with 
MDR1 was further studied by drug uptake experiments, measuring clotrimazole uptake 
into MDCKII-MDR1 cells in the presence and absence of MDR1 inhibitor verapamil to 
see if inhibitor increases the concentrations in the cells.  
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5.4 Drug uptake experiments 
 
5.4.1 CDCF 
 
Concentrations of CDCF in fractions and between cell lines were quite similar in all 
cases (Figure 9-Figure 11). Only difference can be detected in lysate concentrations: 
Somewhat smaller concentrations can be seen in lysates of wild type cells when 
compared to MDR1 transfected cells.  
In our experiments, CDCF did not show the expected behavior of a MDR1 substrate. 
There was no difference in the concentrations of fractions in MDR1 transfected cells 
with or without verapamil. Also, concentration in the plasma membrane of MDR1 
transfected cells was not smaller than in wild type cells. One reason for these results 
may be that CDCF has high affinity to MDR1 (Km value of 3 µM) and quite low Vmax 
so with higher concentrations active transport is saturated and passive uptake dominates, 
and the concentrations in fractions become similar with and without inhibitor. Smaller 
incubation concentrations could not be tested, since the sensitivity of the analysis 
method was not high enough.  
The reason for smaller concentration in lysates of wild type cells may be that 
overexpression of MDR1 protein can change the characteristic of plasma membrane and 
affect the drug permeation through it. Also different passage numbers can cause 
differences between wild type and MDR1 transfected cells, since the passage numbers 
used were 30-33 for wild type cells and 11-16 for MDR1 transfected cells.  
No difference can be seen between uptake profiles of MDR1 transfected cells and wild 
type cells (Figure 12). Average concentrations in plasma membrane are similar or up to 
3-fold larger than concentration in cytoplasm.  
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5.4.2 Clotrimazole 
 
Focusing on MDR1 transfected cells, the difference with and without verapamil can 
only be seen when incubation concentration of clotrimazole is 30 µM (Figure 13). In 
that case, concentrations in lysate and plasma membrane of MDR1 transfected cells 
with verapamil are larger than without verapamil. With incubation concentrations 100 
µM and 200 µM, concentrations in fractions are quite similar (Figure 14 and Figure 15). 
Some differences can be seen between wild type cells and MDR1 transfected cells: with 
incubation concentration 100 µM, concentrations are somewhat larger in lysates of wild 
type cells, and with incubation concentrations 30 and 200 µM, concentrations are 
smaller in wild type cells.  
There has been some inconsistent information about whether or not clotrimazole is a 
substrate of MDR1. In our experiments, clotrimazole did not show the typical behavior 
of the MDR1 substrate in uptake experiments, except with the smallest concentration 
tested, where verapamil seemed to increase concentrations of clotrimazole in the 
fractions. Also, concentration in wild type cells was not the same as in MDR1 cells with 
verapamil. However, as discussed earlier, clotrimazole has high lipophilicity (log D (7.4) 
=4.9) so even if it was a substrate of MDR1, the transporter should function very 
effectively to overcome passive diffusion which has a large role in the permeation of 
highly lipophilic compounds. Minor difference can be seen with the smallest 
concentration 30 µM, and perhaps smaller concentrations should be tested to draw 
conclusions about clotrimazole interaction with MDR1, although detection limits can 
cause problems.   
Different profile is observed when comparing concentrations in the fractions of wild 
type cells and MDR1 transfected cells (Figure 16). When incubation concentration 
increases, concentration in the fractions increases in MDR1 transfected cells. In wild 
type cells, some saturation can be seen when incubation concentration is increased from 
100 µM to 200 µM and with 200 µM concentration in fractions are even smaller than 
with 100 µM. However, reason for this could be e.g. incomplete dissolution of 
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clotrimazole with concentration of 200 µM.  Average concentrations in plasma 
membrane are significantly larger (4- to 10-fold) than in cytoplasm.  
 
5.4.3 Celiprolol 
 
With all the incubation concentrations, it can be seen that concentrations in fractions are 
greatest in MDR1 transfected cells with verapamil and quite similar in wild type- and 
MDR1 transfected cells (Figure 17- Figure 19).  
Celiprolol shows the behavior expected from MDR1 substrates. When MDR1 is 
inhibited with verapamil, concentrations in fractions are more than 10-fold larger than 
without verapamil. However, concentrations in wild type cells are not similar as 
concentrations in MDR1 transfected cells with verapamil. The reason for this may be 
changed permeability of plasma membrane due to overexpression of MDR1 or different 
passage numbers between wild type and MDR1 transfected cells as discussed earlier. 
Also, there could be some constitutional transporters in MDCKII cells, which are also 
inhibited by verapamil and that could explain the difference between MDCKII-wt and 
MDCKII-MDR1 cells with verapamil. 
Uptake profile in MDR1 cells with verapamil deviates from others (Figure 20). When 
MDR1 is inhibited with verapamil, the concentration in plasma membrane of MDR1 
cells is larger than in cytoplasm with the largest incubation concentration 500 µM. With 
smaller concentrations and in other cell types, the concentrations are similar between 
different fractions. This is quite unexpected, since verapamil should increase the 
concentration in all fractions in a similar manner. Perhaps there could be some 
competitive processes involved in the partitioning of celiprolol to the plasma membrane, 
but further studies need to be conducted to clarify the mechanisms responsible for this. 
If incubation concentration is increased further, the effect of the transporter to 
concentrations is expected to increase, however this was not tested because of the quite 
large amounts of celiprolol needed for that. With incubation concentrations 100 and 300 
µM, average concentrations in plasma membrane are similar or up to 3-fold larger than 
in cytoplasm.  
31 
 
 
5.4.4 Effect of lipophilicity to drug distribution 
 
Comparing partitioning of drugs between plasma membrane and cytoplasm, it can be 
seen that the more lipophilic the compound, the larger is its concentration in plasma 
membrane compared to the cytoplasm. Clotrimazole as a lipophilic compound (log D 
(7.4)=4.9) has concentrations in plasma membrane that are 4-10-fold larger than in 
cytoplasm. On the other hand, celiprolol (log D (7.4)=0.1) and CDCF (log D (7.4)=-0.5) 
as less lipohilic compounds have concentrations in plasma membrane similar or up to 3-
fold larger than in cytoplasm.   
This effect of lipophilicity can also be seen in Km(membrane) or Ki(membrane) values. 
Ki(membrane) for lipophilic clotrimazole is 597 µM, more than 13-fold larger than its 
Ki=44 µM. For celiprolol Km(membrane) is only 77 µM, almost 13-fold smaller, than its 
Km=1 mM and for CDCF Km(membrane) is 0.3 µM, 10-fold smaller than its Km=3 µM. 
So with lipophilic compounds, affinity to the MDR1 inside plasma membrane seems to 
be weaker (Km is larger) than expected when Km is determined from the concentrations 
in extracellular fluids. Opposite can be assumed to hold true for hydrophilic compounds. 
Also it can be assumed that because of the low affinity with hydrophobic compounds, 
binding to MDR1 is quite unspecific and perhaps multiple binding sites are involved 
whereas with hydrophilic compounds, the binding is more specific. So when predicting 
the role of active transport in the overall transport process, using Km values determined 
from extracellular fluids can cause overestimation of the role with lipophilic compounds 
and underestimation with hydrophilic compounds. These results are in line with 
previous work by Clay and Sharom, who determined KMlip value (comparable to 
Km(membrane)) for two lipophilic (calculated log P values log P=1.28 for LDS-751 and 
log P=2.96 for Hoechst 33342 (Royal Society of Chemistry 2013)) MDR1 substrates to 
be in the millimolar range (1.5-8.8 mM) whereas the affinity determined from the 
extracellular fluid Km is in the micromolar range (0.8-2.8 µM) (Clay, Sharom 2013). 
Also Meier et al. (2006) reported Km(membrane) values of millimolar range. Although 
as large difference of the Km and Km(membrane) values as was not observed in our work, 
the trend is similar. The reason for different results could be the use of phospholipids 
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monolayers instead of the whole cells used in our experiments. Clay and Sharom 
suggested that total binding affinity of the substrate to MDR1 is determined by both the 
substrate-lipid bilayer-interactions, and the substrate-MDR1-interactions. Our results 
are also in line with that assumption, since lipophilic clotrimazole has most likely larger 
affinity to lipids than less lipophilic celiprolol and CDCF.  
 
5.4.5 Other studies 
 
Quantitative studies determining the intracellular concentrations in plasma membrane 
and cytoplasm are still quite rare, so comparison of our results to others is challenging. 
Campoli et al. measured the concentration of posaconazole in plasma membrane and 
cytosol of pulmonary epithelial cells (A549) (Campoli et al. 2011). The absolute 
concentrations were not determined, but instead the concentrations were normalized to 
protein amounts of the samples. Concentration in plasma membrane was approximately 
10-fold larger than cytosolic concentration, similar magnitude as our results with 
clotrimazole, which is expected since posaconazole is also a lipophilic compound (log 
P >3, (Courtney et al. 2004).    
 
5.5 The applicability, challenges and further improvement of isolation protocol 
 
The protocol for plasma membrane isolation introduced here can be used to study 
concentration in plasma membrane and cytoplasm of cells. One great advantage of this 
protocol is that the intracellular concentrations of non-fluorescent compounds can be 
determined, unlike with the most frequently used methods utilizing fluorescent 
microscopy. For drugs with intracellular targets, knowing the concentration of a drug in 
the site of action greatly improves the predictability of the pharmacological response. 
The same concerns also drug-transporter interaction and the effect of the active 
transport can be more accurately predicted knowing the concentrations in the transporter 
binding site. This protocol is not suitable for high-throughput measurements since the 
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volumes needed are large. The protocol is also quite laborious, including many steps, 
and is more valuable as a research tool to measure intracellular concentrations and to 
study partition of drugs between plasma membrane and cytoplasm.   
One limiting factor in this protocol is the sensitivity of the analysis method. 
Experiments have to be conducted in T75 flasks, since with smaller culture bottles or 
well plates, the amount of plasma membrane and consequently concentration of drug in 
plasma membrane fraction becomes too small to detect. The large deviation seen 
especially with concentration in plasma membrane is most likely due to difficulties in 
re-suspending the pellet after the last centrifugation, since the pellet was so scarce and 
almost nonvisible in some experiments. There was also quite large deviation in the 
amount of cells in different flasks which is unexpected, since all the flasks are treated 
similarly and should contain approximately the same amount of cells. There could be 
many reasons for this, for example mixing could have been insufficient before dividing 
cells to new flasks or before taking sample to cell count. This deviation in the cell 
amounts reflects also to concentrations calculated based on cell count.  
The protocol can be improved further. Homogenization can be improved e.g. by adding 
ammonium hydroxide or other detergent to cell suspension before homogenization. This 
pretreatment lyses the cells and can increase the fraction of the broken cells. The 
fraction of broken cells after homogenization was 70-85 % in most of the experiments 
but fractions as low as 45 % were measured. Since the amount of the broken cells was 
taken into account when calculating concentrations and the fraction of the broken cells 
in most of the cases was quite large, addition of the detergent was not essential. Also, 
detergent addition may result in detachment of the drug from the plasma membrane. 
However, if the concentration in the plasma membrane fraction is near analysis 
detection limit, the addition of the detergent after plasma membrane isolation can 
improve the reliability of the results. Cell count can be determined also by other 
methods. One option to determine cell count is to measure the protein concentration of 
the samples e.g. by Bradford method and proportion protein concentration to cell 
amount. This could be done after isolation of the fractions and the exact amount of 
protein in the samples could be determined. In our experiments, cell count was 
determined before and after homogenization but the amount of broken cells in fractions 
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can be smaller if some material gets lost during the isolation protocol. However, cell 
count by Cedex XS was fast and easy and it seemed more reasonable to count cells 
directly than determine the cell count indirectly from protein concentrations. Diffusion 
of the drug can be a problem in fractionation based methods of isolation. Whether or not 
working on the ice is sufficient to inhibit the diffusion should perhaps be examined for 
this protocol.  
 
 
6 CONCLUSIONS 
 
The protocol for isolation of plasma membrane and cytoplasm introduced in this work 
can be used to study intracellular partition of drugs. It is most valuable as a research tool 
in the later phases of the drug development, when the lead compound is already selected, 
since the protocol is quite laborious and not applicable for high throughput screening. In 
this work, it was used to study the plasma membrane and cytoplasm concentrations of 
three drugs with different lipophilicity and MDR1 interaction. Celiprolol concentrations 
in the fractions followed the trend expected for MDR1 substrates but CDCF and 
clotrimazole concentrations did not. It was found out that as expected, the partitioning 
of lipophilic compound (clotrimazole) into plasma membrane is larger than partition of 
hydrophilic compound (CDCF and celiprolol). Lipophilicity affected also to the 
Km(membrane) or Ki(membrane) values determined for compounds, with clotrimazole 
Ki(membrane) value being larger than respective Ki value, and CDCF and celiprolol 
Km(membrane) being smaller than their respective Km values.  
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 APPENDIX 1 
Protocol for isolation of cell organelles 
1. Detach cells from the bottom of the culture flask by cell scraper, centrifuge at 
400g for 5 min at 4 °C. Resuspend pellet with 10 ml of cold PBS. Centrifuge 
suspension at 400g for 5 min at 4 °C.  
2. Resuspend pellet with 5 ml of cold PBS and homogenize using Dounce 
homogenisator and 40 up and down strokes. Incubate for 1 hour on ice and take 
sample A (150 microl). 
3. Centrifuge at 100 g for 2 min at 4 °C to remove unbroken cells and 600g for 10 
min at 4 °C to remove nuclei. 
4. Centrifuge at 15 000 g for 5 min at 4 °C to remove mitochondria, lysosomes and 
peroxisomes. Resuspend pellet with 200 µl of PBS (sample B). 
5. Centrifuge supernatant at 100 000g for 1 hour at 4 °C to remove plasma 
membrane. Resuspend pellet with 200 µl of PBS (sample C). Supernatant is 
sample D (cytoplasm). 
  
 APPENDIX 2.  
Standard curve for CDCF  
Standard curve for CDCF 22.3.2013 
     
       Concentration of CDCF 
(µM) 
Fluorescence (RFU) Average SD SD (%) 
0.05 50.6400 49.1500 47.4100 49.0667 1.6166 3.2947 
0.01 9.8360 9.5650 10.0300 9.8103 0.2336 2.3808 
0.005 5.2840 4.9590 5.0900 5.1110 0.1635 3.1993 
0.001 1.1640 1.0410 1.1640 1.1230 0.0710 6.3236 
0.0005 0.6682 0.5897 0.7375 0.6651 0.0739 11.1177 
0.0001 0.2480 0.2882 0.2657 0.2673 0.0201 7.5375 
0 0.1588 0.1468 0.1657 0.1571 0.0096 6.0878 
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 APPENDIX 3 
Assay steps in vesicle study 
1. Mix 1000 µl of membrane suspension with 3925 µl Assay mix. Add 75 µl 50 
µM CDCF. Mix well, but gently! Add 50 µl of the suspension to each well on a 
standard 96-well plate. 
2. Add test drugs (in 0.75 µl DMSO) and DMSO as indicated on the plate setup. 
3. Mix 90 µl of Mg-ATP with 1410 µl assay mix.  
4. Preincubate the plate, 1500 µl Mg-ATP solution and assay mix for 10 min at 
37 °C. 
5. Start the reaction by adding 25 µl of the MgATP solution or Assay mix to 
appropriate wells as indicated on the plate setup. Incubate the plate at 37 °C for 
30 min. 
6. Wet the filters with 100 µl of distilled water per well and set up the filtering 
apparatus. 
7. Stop the reaction by adding 200 µl of ice-cold Washing mix to the wells. 
Transfer the samples from the 96-well plate to the filter plate and filter. 
8. Wash the wells 5 times with 200 µl washing mix (should be done in 2 
minutes from stopping the reaction). 
9. Dry the filters. 
10. Add 100 µl of 0.1 M NaOH to each well and incubate for 10 min. Transfer 
the liquid under vacuum to a clear, flat-bottom 96-well plate. 
11. Measure fluorescence at Ex: 510 nm and Em: 535 nm. (bandwith 12 nm + 
scan 450-510 nm to pdf) 
 
 
  
7 8 9 10 11 12
A Clotrimazole 1 µM
B Clotrimazole 10 µM
C Clotrimazole 100 µM
D 0.5 µM CDCF + 5 µM Clotrimazole
E 0.5 µM CDCF + 50 µM Clotrimazole
F 0.5 µM CDCF + 100 % DMSO
+ ATP - ATP
 APPENDIX 4 
Concentrations in drug uptake experiments 
CDCF 30 µM 
       
 
MDR1, 27.5 
   
wt 8.7 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 1.193 3.579 0.736 
 
average 0.184 1.197 1.498 
std.dev 0.012 3.222 0.048 
 
std.dev 0.055 0.550 0.583 
         
 
 + verapamil, MDR1, 27.5 
       lysate membrane cytoplasm 
     average 1.526 5.632 1.518 
     std.dev 0.326 4.164 0.312 
                       
CDCF 100 µM 
       
 
MDR1, 25.4&29.4 
   
wt 8.7 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 2.130 6.249 3.122 
 
average 0.852 10.705 3.185 
std.dev 0.049 2.636 1.081 
 
std.dev 0.012 2.691 0.199 
         
 
 + verapamil, MDR1, 25.4&29.4 
  
wt 1.4 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 2.585 7.469 2.816 
 
average 1.286 7.534 3.986 
std.dev 0.866 4.721 0.119 
 
std.dev 0.221 1.947 2.178 
                  
CDCF 200 µM 
       
 
MDR1, 6.6 
   
MDR1, 10.6 
   lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 4.689 5.965 8.945 
 
average 11.245 24.820 15.599 
std.dev 2.380 3.383 5.344 
 
std.dev 0.529 7.458 1.233 
         
 
 + verapamil, MDR1, 6.6 
  
wt 8.7 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 4.207 12.918 10.376 
 
average 1.456 13.477 4.446 
std.dev 0.968 9.683 6.976 
 
std.dev 0.305 0.673 1.389 
          
 
 
 Clotrimazole 30 µM 
       
 
MDR1, 23.5 
   
wt, 17.6 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 102.759 420.561 45.389 
 
average 44.898 520.424 50.6211 
std.dev 16.659 122.502 6.163 
 
std.dev 12.189 475.488 35.612 
         
 
 + verapamil, MDR1, 30.5 
       lysate membrane cytoplasm 
     average 196.829 903.220 83.155 
     std.dev 76.308 255.264 48.373 
                       
Clotrimazole 100 
µM 
       
 
MDR1, 23.5 
   
MDR1, 10.6 
   lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 387.3813 3335.589 436.884 
 
average 367.457 1941.091 155.712 
std.dev 120.114 1207.367 236.909 
 
std.dev 50.414 1302.649 35.3608 
         
 
 + verapamil, MDR1, 23.5 
  
wt, 8.4 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 366.680 2283.280 274.100 
 
average 885.107 2541.881 400.709 
std.dev 41.262 709.193 127.681 
 
std.dev 166.973 226.941 32.835 
                  
Clotrimazole 200 
µM 
       
 
MDR1, 6.6 
    
wt 17.6 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 1824.378 6725.089 946.363 
 
average 345.894 1067.423 167.932 
std.dev 95.599 3375.062 772.654 
 
std.dev 56.133 377.553 7.958 
         
 
 + verapamil, MDR1, 3.6 
       lysate membrane cytoplasm 
     average 1329.633 3710.589 894.360 
     std.dev 122.319 928.677 204.253 
     
          
 
 
 
 
 Celiprolol 100 µM 
       
 
MDR1, 29.4 
   
 MDR1, uusinta, 10.6 
  lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 4.694 21.063 8.327 
 
average 3.685 15.077 8.956 
std.dev 0.161 29.788 1.927 
 
std.dev 1.025 21.322 3.976 
         
 
 + verapamil, MDR1, 29.4 
  
wt, 24.6 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 200.397 456.229 175.765 
 
average 2.933 23.762 7.179 
std.dev 115.315 105.843 28.304 
 
std.dev 0.154 23.033 1.663 
                  
Celiprolol 300 µM 
       
 
MDR1, 30.5 
   
wt 24.6 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 4.274 20.180 7.085 
 
average 10.859 16.614 21.209 
std.dev 1.601 5.273 4.808 
 
std.dev 0.650 7.019 1.841 
         
 
 + verapamil, MDR1, 30.5 
       lysate membrane cytoplasm 
     average 199.349 364.133 397.919 
     std.dev 22.025 45.852 10.010 
                       
Celiprolol 500 µM 
       
 
MDR1, 3.6 
   
wt 24.6 
    lysate membrane cytoplasm 
 
  lysate membrane cytoplasm 
average 27.960 45.827 66.905 
 
average 44.603 119.688 101.111 
std.dev 5.063 14.290 36.009 
 
std.dev 12.772 70.247 49.347 
         
 
 + verapamil, MDR1, 3.6 
       lysate membrane cytoplasm 
     average 327.133 1762.075 756.772 
     std.dev 98.182 646.507 208.636 
     
         
         extrapolated from calibration curve 
     
          
